 
 
TPL-000052_v11  
Selexipag / ACT-[ADDRESS_1045972] of selexip ag on daily life 
physical activity and patient’s se lf-reported symptoms and thei r impacts 
 
Study Phase: [ADDRESS_1045973] Number: 2017-000216-42  
Status and version: Final Version 2  
Date: 5 December 2018 
Document type Global protocol 
Actelion document number (Doc No.): D-18.[ADDRESS_1045974]. It is understood that this information will not be disclosed to others without written authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent from those persons to whom the study treatment may be administered. 
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 2/[ADDRESS_1045975] DETAILS 
Sponsor  
 Actelion Pharmaceuticals Ltd  
Gewerbestrasse 16  
CH-4123 Allschwil 
Switzerland  
 [PHONE_4468] [ADDRESS_1045976] details of the Clinical Trial Physician can 
be found in the Investigator Site File  
Medical  Emergency Hotline  
Toll phone number: [number] Site-specific toll telephone numbers and toll -free 
numbers for the Medical Emergency Hotline can be 
found in the Investigator Site File  
 
 
ACTELION CONTRIBUTORS TO THE PROTOCOL 
Clinical Trial Scientist   PhD  
 
Clinical Trial Statistician  Yoko Shiraga , MSc  
 
Clinical Trial Physician  Maziar Assadi Gehr, MD  
 
Drug Safety Physician   MD 
 
 
COORDINATING INVESTIGATOR 
[CONTACT_5627] / Title  Address  
Ioana Preston, MD  Tufts Medical Center,  US 
  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 3/[ADDRESS_1045977] RESEARCH ORGANIZATIONS INFORMATION 
 
CENTRAL LABORATORY   
  
 [LOCATION_003]  
CENTRAL RANDOMIZATION   
, [LOCATION_003]  
CRO  (study conduct)  Chiltern International Ltd,  
[ADDRESS_1045978],  
Slough, Berkshire SL1 4AA, [LOCATION_006]  
CRO (ePRO and actigraphy)  Exco InTouch Limited,  
Unit 6, Wheatcroft Business Park,  
Landmere Lane,  
Nottingham, NG12 4DG, [LOCATION_006]  
Biostatistics  
 
 [LOCATION_013]  
A list of site -specific contact [CONTACT_763386] (CROs) can be 
found in the Investigator Site File.  
  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 4/[ADDRESS_1045979] 2017 -000216 -42 
Doc No D -18.398  
 
SIGNATURE [CONTACT_180548] / number  
Selexipag  / ACT -293987 
Indication 
Pulmonary arterial hypertension  
Protocol number, study acronym, study title 
AC-065A404, TRACE:  A multi -center, double -blind, placebo -controlled, Phase [ADDRESS_1045980] of selexipag on daily 
life physical activity and patient’ s self -reported symptoms and their impacts. 
I approve the design of this study. 
 
 
[COMPANY_003]
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 5/[ADDRESS_1045981] 2017 -000216 -42 
Doc No D -18.398  
 
INVESTIGATOR SIGNATURE [CONTACT_180549] / number 
Selexipag  / ACT -293987 
Indication 
Pulmonary arterial hypertension  
Protocol number, study acronym, study title 
AC-065A404, TRACE : A multi -center, double -blind, placebo -controlled, Phase [ADDRESS_1045982] of selexipag on daily 
life physical activity and patient’ s self -reported symptoms and their impacts. 
I agree to the terms and conditions relating to this study as defined in this protocol, the Case Report Form (CRF), and any other protocol
-related documents. I fully understand 
that any changes instituted by [CONTACT_093](s) without previous agreement with the 
sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study patient s (other than those procedures necessary for the 
wellbe ing of the patient s). 
I agree to conduct this study in accordance with the latest versions, respectively, of the Declaration of Helsinki principles  (currently 2013 version), International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable regulations and laws. I will obtain approval by [CONTACT_215198] (IEC/IRB) prior to study start and signed informed consent from all patient s included in this study. If an amendment to the protocol is necessary, I 
will obtain approval by [CONTACT_18369]/IRB and ensure approval by [CONTACT_208179], and I will re
-consent the patient s (if applicable). I will allow dire ct access to source documents 
and study facilities to sponsor representative(s), particularly Clinical Research Associate(s) (CRA[s]) and auditor(s), and agree to inspection by [CONTACT_208180]/IRB representative(s). I will ensure that the study treatment(s) supplied by [CONTACT_208181]/are being used only as described in this protocol. I will ensure that all patient s 
or legally designated representatives have understood the nature, objectives, benefits, implications, risks and inconveniences for  participating in this study. During the conduct 
of the study, I will constantly monitor the risk/benefit balance for an individual patient . I 
confirm herewith that the sponsor is allowed to enter and utilize my professional contact [CONTACT_763387]. 
 Country  Site 
number  Town  Date   Signature  
[INVESTIGATOR_97159]        
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 6/[ADDRESS_1045983] OF ABBREVIATION S AND ACRONYMS  ..........................................................12  
PROTOCOL SYNOPSIS AC -065A404 ............................................................................ 17 
PROTOCOL  ......................................................................................................................31  
1 BACKGROUND  .........................................................................................................31  
1.1 Indication ......................................................................................................31  
1.2 Study treatment  .............................................................................................31  
1.2.1  Nonclinical results  ............................................................................31  
1.2.2  Clinical pharmacology  ......................................................................32  
1.2.3  Clinical efficacy  ................................................................................32  
1.2.4  Summary of safety profile  ................................................................32  
1.3 Purpose and rationale of the study ................................................................33  
1.4 Summary of known and potential risks and benefits ....................................34  
2 STUDY OBJECTIVES  ...............................................................................................34  
2.1 Primary objective  ..........................................................................................34  
2.2 Secondary objectives ....................................................................................34  
2.3 Other objectives  ............................................................................................35  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................35  
3.1 Study design .................................................................................................35  
3.1.1  Study periods ....................................................................................35  
3.1.2  Study duration ...................................................................................37  
3.2 Study design rationale ..................................................................................37  
3.3 Study committees  .........................................................................................38  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 7/[ADDRESS_1045984] 2017 -000216 -42 
Doc No D -18.398  
 
4 PATIENT POPULATION ..........................................................................................38  
4.1 Patient population description ......................................................................38  
4.2 Rationale for the selection of the study population ......................................38  
4.3 Inclusion criteria  ...........................................................................................39  
4.4 Exclusion criteria  ..........................................................................................40  
4.5 Criteria for women of childbearing potential ...............................................42  
4.5.1  Definition of childbearing potential ..................................................42  
4.5.2  Acceptable methods of contraception ...............................................42  
5 TREATMENTS  ..........................................................................................................43  
5.1 Study treatment  .............................................................................................43  
5.1.1  Investigational treatment: Description and rationale  ........................43  
5.1.2  Matching placebo: Description and rationale ...................................44  
5.1.3  Study treatment administration  .........................................................44  
[IP_ADDRESS]  Individualized dose titration (Weeks 1 to 12) .........................44  
[IP_ADDRESS]  Individualized maintenance dose (Weeks 13 to 24) ................45  
5.1.4  Treatment assignment  .......................................................................46  
5.1.5  Blinding ............................................................................................46  
5.1.6  Unblinding ........................................................................................47  
[IP_ADDRESS]  Unblinding for final analyses ..................................................47  
[IP_ADDRESS]  Unblinding for interim analyses ..............................................47  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse 
reactions ...................................................................................47  
[IP_ADDRESS]  Emergency procedure for unblinding ......................................47  
5.1.7  Study t reatment supply .....................................................................47  
[IP_ADDRESS]  Study treatment packaging and labeling  .................................48  
[IP_ADDRESS]  Study treatment distribution and storage .................................48  
[IP_ADDRESS]  Study treatment dispensing .....................................................48  
[IP_ADDRESS]  Study treatment return and destruction ...................................48  
5.1.8  Study treatment accountability and compliance with study treatment  ...........................................................................................49
 
[IP_ADDRESS]  Study treatment accountability  ................................................49  
[IP_ADDRESS]  Study treatment compliance  ....................................................49  
5.1.9  Study treatment dose adjustments and interruptions ........................50  
5.1.10  Premature discontinuation of study treatment  ..................................50  
5.1.11  Study -specific criteria for interruption / permanent 
discontinuation of study treatment .................................................... 51 
[IP_ADDRESS]  Hemoglobin abnormalities  ......................................................51  
[IP_ADDRESS]  Severe hepatic impairment  ......................................................52  
[IP_ADDRESS]  Start of a CYP2C8 inhibitor ....................................................52  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 8/[ADDRESS_1045985] 2017 -000216 -42 
Doc No D -18.398  
 
[IP_ADDRESS]  Pregnancy  ................................................................................52  
[IP_ADDRESS]  Hyperthyroidism ......................................................................52  
5.2 Previous and concomitant therapy ................................................................52  
5.2.1  Definitions  ........................................................................................52  
5.2.2  Recording of previous/concomitant therapy .....................................52  
5.2.3  Allowed concomitant therapy ...........................................................53  
5.2.4  Forbidden concomitant therapy ........................................................53  
5.2.5  Rescue therapy  ..................................................................................53  
6 STUDY ENDPOINTS  ................................................................................................53  
6.1 Efficacy endpoints ........................................................................................53  
6.1.1  Primary efficacy endpoint(s)  ............................................................53  
6.1.2  Secondary efficacy endpoints ...........................................................54  
6.1.3  Other efficacy endpoints ...................................................................54  
6.2 Safety endpoints  ...........................................................................................54  
6.3 Biomarkers  ....................................................................................................55  
7 STUDY ASSESSMENTS  ...........................................................................................55  
7.1 Patient characteristics  ...................................................................................55  
7.1.1  Informed consent signature (Visit 1) ................................................55  
7.1.2  Demographics (Visit 1) .....................................................................55  
7.1.3  Documentation of PAH disease (Visit 1) .........................................56  
7.1.4  Medical history (Visit 1)  ...................................................................56  
7.1.5  Previous and concomitant therapi[INVESTIGATOR_014] .................................................56  
7.1.6  Eligibility, randomization (Visit 1 and Visit 2)  ................................[ADDRESS_1045986]® ............................................... 60 
7.6 Additional assessments for women ..............................................................60  
7.6.1  Childbearing potential .......................................................................60  
7.6.2  Contraception check (women of childbearing potential only) ..........61  
7.6.3  Pregnancy tests (wo men of childbearing potential only) ..................61  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 9/[ADDRESS_1045987] 2017 -000216 -42 
Doc No D -18.398  
 
8 VISIT SCHEDULE  .....................................................................................................61  
8.1 Site visits  .......................................................................................................61  
8.1.1  Visit 1: Screening/re -screening ......................................................... 61 
8.1.2  Visit 2: Randomization  .....................................................................63  
8.1.3  Visit 3: Intermediate Visit .................................................................63  
8.1.4  Visit 4: End of treatment visit  ...........................................................[ADDRESS_1045988] -STUDY TREATMENT / MEDICAL 
CARE  .......................................................................................................................... 66 
9.1 Study completion as per protocol .................................................................66  
9.2 Premature withdrawal from study  ................................................................66  
9.3 Premature termination or suspension of the study ........................................67  
9.4 Medical care of patients after study completion / withdrawal from 
study ..............................................................................................................68  
10 SAFETY DEFINITIO NS AND REPORTING REQUIREMENTS  ...........................68  
10.1  Adverse events  ..............................................................................................68  
10.1.1  Defini tion of adverse events .............................................................68  
10.1.2  Intensity of adverse events  ................................................................69  
10.1.3  Relationship to study treatment ........................................................70  
10.1.4  Recording of adverse events  .............................................................70  
10.1.5  Follow -up of adverse events ............................................................. 70 
10.2  Serious adverse events  ..................................................................................70  
10.2.1  Definitions of serious adverse events ...............................................70  
10.2.2  Reporting of serious adverse events .................................................71  
10.2.3  Follow -up of serious adverse events ................................................. 71 
10.2.4  After the [30 -day] follow -up period ................................................. 71 
10.2.5  Reporting procedures ........................................................................71  
10.3  Pregnancy  .....................................................................................................72  
10.3.1  Reporting of pregnancy ....................................................................72  
10.3.2  Follow -up of pregnancy .................................................................... 73 
10.4  Study safety monitoring  ................................................................................73  
11 STATISTICAL METHODS  .......................................................................................73  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 10/[ADDRESS_1045989] 2017 -000216 -42 
Doc No D -18.398  
 
11.1  Analysis sets  .................................................................................................73  
11.1.1  Screened Analysis Set  .......................................................................73  
11.1.2  Full Analysis Set ...............................................................................73  
11.1.3  Per-protocol Analysis Set ................................................................. 73 
11.1.4  Safety Set  ..........................................................................................74  
11.1.5  Usage of the analysis sets  .................................................................74  
11.2  Variables  .......................................................................................................74  
11.2.1  Primary efficacy variables  ................................................................74  
11.2.2  Secondary efficacy variables  ............................................................74  
11.2.3  Other efficacy variables  ....................................................................75  
11.2.4  Safety variables  .................................................................................75  
11.3  Description of statistical analyses  .................................................................75  
11.3.1  Overall testing strategy  .....................................................................75  
11.3.2  Analysis of the primary efficacy variables  .......................................75  
[IP_ADDRESS]  Hypotheses and statistical model ............................................76  
[IP_ADDRESS]  Handling of missing data  .........................................................76  
[IP_ADDRESS]  Main analysis  ...........................................................................76  
[IP_ADDRESS]  Supportive/sensitivity analyses  ...............................................76  
[IP_ADDRESS]  Sub-group analyses  .................................................................. 76 
11.3.3  Analysis of secondary efficacy variables  ..........................................77  
[IP_ADDRESS]  PAH -SYMPACT® ................................................................... 77 
[IP_ADDRESS]  Othe rs PAH related clinical outcomes  ....................................77  
[IP_ADDRESS]  Association between actigraphy and others efficacy 
endpoints .................................................................................77  
11.3.4  Analysis of the safety variables  ........................................................77  
[IP_ADDRESS]  Adverse events  ........................................................................78  
[IP_ADDRESS]  Laboratory variables  ................................................................78  
[IP_ADDRESS]  Vital signs and body weight ....................................................79  
11.3.5  Exposure to study drug .....................................................................79  
11.3.6  Baseline characteristics and concomitant medications  .....................79  
11.4  Interim analyses  ............................................................................................79  
11.5  Sample size  ...................................................................................................79  
12 DATA HANDLING  ....................................................................................................80  
12.1  Data collection  ..............................................................................................80  
12.2  Maintenance of data confidentiality  .............................................................81  
12.3  Database management and quality control  ...................................................81  
13 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................82  
13.1  Ethics and Good Clinical Practice  ................................................................82  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 11/[ADDRESS_1045990] 2017 -000216 -42 
Doc No D -18.398  
 
13.2  Independent Ethics Committee / Institutional Review Board  ......................82  
13.3  Informed consent ..........................................................................................83  
13.4  Compensation to patients and investigators .................................................84  
13.5  Protocol adherence/compliance  ....................................................................[ADDRESS_1045991] OF TABLES 
 
Table 1  Study periods, visits at study site and assessments  ....................................28  
Table 2  Telephone calls from the study site to the patient, and assessments ..........30  
Table 3  Recommended  double -blind up -titration scheme  ...................................... 45 
Table 4  Confidence interval (2 -sided 5%) width assuming different scenarios 
of SD  .......................................................................................................... [ADDRESS_1045992]® Questionnaire .............................................................. 99 
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 12/[ADDRESS_1045993] tolerated d ose  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 13/[ADDRESS_1045994] 2017 -000216 -42 
Doc No D -18.398  
 
IB  Investigator’ s B rochure  
ICF  Informed Consent Form 
ICH  International Council for Harmonisation  
IEC  Independent Ethics Committee 
IMD   Individualized m ain tenance dose  
INN  International nonproprietary name 
[CONTACT_763439] e 
mPAP   Mean pulmonary a rte rial pressure  
MedDRA   Medical Dictionary for Regulatory Activities  
NT-proBNP   N-terminal pro b -type natriuretic peptide  
PAH  Pulmonary arterial hypertension  
PAH -SYMPACT®  Pulmonary Arterial Hypertension Symptoms and Impact  
PAP  Pulmonary artery pressure 
PAWP   Pulmonary artery wedge pressure  
PDE -5  Phosphodiesterase -5  
PH  Pulmonary hypertension 
PI  [INVESTIGATOR_678]  
p.o.  Oral 
PPS  Per-protocol Analysis Set  
PRO   Patient -reported outcome  
PVR   Pulmonary vascular resistance  
QoL  Quality of Life  
QS  Quality System 
RHC   Right heart catheterization  
RSI  Reference safety information  
SAE   Serious adverse event  
SAP  Statistical Analysis Plan  
SBP  Systolic blood pressure 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 14/[ADDRESS_1045995] Information  
WASO   Wake after sleep onset 
WHO  World Health Organization  
WU  Wood Units 
 
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 15/[ADDRESS_1045996] 2017 -000216 -42 
Doc No D -18.398  
 
SUBSTANTIAL GLOBAL AMENDMENT 1  
Amendment rationale 
This amendment applies to global protocol AC -065A404, Version 1, dated 23 February 
2017. The resulting amended global protocol is Version 2, dated 5 December  2018. 
The reasons for this amendment are as follows:  
Update of the dosing instructions for selexipag/placebo study drug , based on a recent 
drug-drug interaction study with a moderate CYP2C8 inhibitor, clopi[INVESTIGATOR_7745], as described 
in the Investigator Brochure version 13 of Sep tember  2018. In case of  concomitant 
administration of a moderate inhibitor of CYP2C8 (e.g., clopi[INVESTIGATOR_7745], deferasirox, 
teriflunomide) the dosing frequency of selexipag/placebo should be reduced to once daily  
and reverted to twice a day when co -administration of moderate CYP2C8 inhibitor is 
stopped. 
Exclusion Criterion [ADDRESS_1045997] of assessments has been modified without affecting endpoint variables . The 
sampling for blood biomarkers  is not  repeated at re -screening  if the sampling has been 
performed at the initial screening , and there is no interaction with the Interactive 
Response Technology system at end of study.  
Reference to the current Investigator Brochure Ver sion 13, dated September 2018, is 
made as applicable.  
Changes to the protocol 
Two versions of the amended protocol will be prepared: 1) a clean version and 2) a Word comparison document, showing deletions and insertions in comparison to the previous protocol version. 
Amended protocol sections 
The main sections of the protocol affected by [CONTACT_763388]. Where 
applicable, the same changes have also been made to the corresponding sections of the protocol synopsis: 
Table 1  Study
  periods, visits at study site and assessments  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 16/[ADDRESS_1045998] 2017 -000216 -42 
Doc No D -18.398  
 
4.4 Exclusion criteria  
5.1.1 In vestigational treatment: Descriptio n and rationale 
5.1.2 Matching placebo: Description and rationale 
[IP_ADDRESS] Individualized dose titration (Weeks 1 to 12) Table 3  Re
 commended double -blind up- titration scheme  
[IP_ADDRESS]  Start of a CYP2C8 inhibitor 
8.1.1 Vi sit 1: Screening/re- screening  
14 RE FERENCES  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 17/[ADDRESS_1045999] of selexipag on daily life physical activity and patient’ s 
self-reported symptoms and their impacts  
ACRONYM  TRACE: EffecT of selexipag on daily life physical activity 
assessed by a weaRAble deviCE  
OBJECTIVES  Primary objective  
• Evaluate the effect of selexipag on daily life physical 
activity (DLPA) of patients with pulmonary arterial 
hypertension ( PAH). 
Secondary objectives  
• Evaluate the effect of selexipag on PAH symptoms and 
th
eir impacts in patients ’ daily life.  
• Evaluate the effect of selexipag on exercise capacity, and 
d
isease severity  in patients with PAH . 
• Evaluate the safety a nd tolerability of selexipag in patients 
with PAH. 
Other objectives  
• Explore potential association between traditional efficacy 
outcomes and DLPA .  
• Explore the levels and level changes of biomarkers 
potentially associated with PAH.  
DESIGN  A prospective, multi -center, double -blind, randomized, 
placebo -controlled, parallel -group, exploratory Phase 4 study. 
PERIODS  Screening  period (duration up to 14 days): The period 
includes the informed consent process and assessments 
determining patient eligibility at Visit 1. Some of the 
assessments provid e baseline data. At Visit [ADDRESS_1046000]® are given to 
the patient for outpatient use . Visit 2  defined as Day 1  is being 
scheduled . 
Baseline  period ( duration 14–28 days):  The period starts at 
the end of Visit 1 and ends with randomization at Visit 2 on 
Day 1. The actigraphy device is worn for the entire period, 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 18/[ADDRESS_1046001] 2017 -000216 -42 
Doc No D -18.398  
 
24 hours per day (except during charging) for the collection of 
baseline DLPA. The recording  of DLPA  starts on the day of 
Visit [ADDRESS_1046002]® is assessed daily over a period 
of 7 days  starting on Day  −14. The start of the 
PAH -SYMPACT® can be delayed until Day  −11, if the start on 
Day −[ADDRESS_1046003]® are required for eligibility .  
Treatment period ( duration 24 weeks ): For eligible patients 
with valid baseline data for DLPA and PAH -SYMPACT®, the 
period starts on Day 1 (Visit 2) with confirmation of eligibility 
and randomization to one of the two double -blind treatment 
arms. Patients will receive the first dose of study treatment on Day 1. From Day 1 up to end of Week 12 (Day 85 ) study 
treatment will be titrated to the highest individually tolerated 
dose. Pat ients will be called weekly by [CONTACT_763389], assess safety/tolerability, and support compliance with the actigraphy device
. From Week [ADDRESS_1046004] tolerated dose  (HTD) is 
intended to be maintaine d (individual ized maintenance dose  
[IMD ]). Change of study treatment dose is allowed if needed 
for efficacy or tolerability reasons.  
Patients will continue to wear the actigraphy device during the whole [ADDRESS_1046005]® is assessed by [CONTACT_763390] (home, vacation, etc.). Patients will be called by [CONTACT_763391]
-SYMPACT® assessment 
period (Week 15 and Week 23) and at Week 20, to assess 
safety/tolerability, and to support  compliance with the 
actigraphy device and the PAH -SYMPACT®. Visits at the 
study site are scheduled on Day 1 (Visit 2), Week 16/Day 113 (Visit 3), and Week 24/Day 169 (Visit 4). An unscheduled visit 
is required for study treatment dispensing if dose is i ncreased 
after Visit 3.  At Visit 4, study treatment is terminated (end
-of-
treatment, EOT). Upon premature discontinuation of study 
treatment  prior to Week 24, the Visit [ADDRESS_1046006]-treatment s afety follow -up period ( duration 30 days):  
This period starts [ADDRESS_1046007] day of 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 19/[ADDRESS_1046008] 2017 -000216 -42 
Doc No D -18.398  
 
intake of study drug. Patients will be followed by [CONTACT_763392] (AEs) at 
investigator ’s discretion. The period is completed by [CONTACT_70705] -of-
study (EOS) telephone call 30 days after EOT . This telephone 
call represent s the end of the patient’ s study participation.  
At any time during the study, unscheduled tele phone calls or  
visits at the study site may be conducted if medically indicated 
at the discretion of the investigator.  
PLANNED DURATION Approximately [ADDRESS_1046009] visit.  
SITE(S)  
/ COUNTRY(IES)  The study will be conducted at approximately 45 sites in 
approximately 12 countries. 
SUBJECTS / GROUPS  Approximately 10 0 patient s will be randomized in a  1:1 ratio to 
the two treatment groups (approximately 50 patients per 
group), stratified by [CONTACT_11338] (Europe/ rest of the world versus 
North America).  
INCLUSION CRITERIA  1. Signed informed consent prior to initiation of any study 
mandated procedure. 
2. Male and female patients with symptomatic PAH, aged from 
18 years to 75 years inclusive. A w oman of childbearing 
potential [ see definition in Section 4.5.1]  is eligible only if 
t
he following applies: 
a) Negative serum pregnancy test at S cr eening Visit [ADDRESS_1046010] at randomization , 
AND  
b) Agreement to undertake monthly urine pregnancy tests 
during the study up to 30 days after study treatment 
discontinuation AND  
c) Agreement to use an acceptable method of contraception 
[see definition in Section 4.5.2] from screening to 
30 
days after study treatment discontinuation . 
3. Diagnosis of PAH belonging to one of the following 
subgroups of Group 1 pulmonary hypertension (PH) 
according to the updated clinical classification  
[Galiè 2015a ]:  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 20/[ADDRESS_1046011] 2017 -000216 -42 
Doc No D -18.398  
 
1.1. Idiopathic (IPAH)  
1.2. Heritable (HPAH)  
1.3. Drugs or toxins induced 
1.4.
 Associated (APAH) with one of the following: 
1.4.1.
 Connective tissue disease  
1.4.2.
 Human immunodeficiency virus (HIV) infection 
1.4.4. Congenital heart disease with simple systemic -
to-pulmonary shunt (atrial septal defect, 
ventricular septal defect, patent ductus arteriosus) 
≥ 1 year after surgical repair. 
4. Documented hemodynamic diagnosis of PAH by [CONTACT_137910] (RHC). Prior 
to randomization the most 
recently performed RHC at rest showing: 
a) Mean pulmonary arterial pressure (mPAP) ≥  25 mmHg; 
and 
b) Resting pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm
-5 or 3 Wood Units ; and  
c) Pulmonary arte ry wedge pressure (PAWP)  or left 
ventricular end diastolic pressure  (LVEDP)  
≤ [ADDRESS_1046012] (ERA) for 
at least 90 days and on a stable dose for 30 days prior to 
randomization.  
6. Possible treatment with a phosphodiesterase -5 (PDE -5) 
inhibitor or soluble guanylate cyclase (sGC)  stimulator must 
be ongoing for at least 90 days and on a stable dose for 30 days prior to randomization. 
7. WHO functional class (FC) II or III  at randomization. 
8. 6-minute walk distance (6MWD) ≥  [ADDRESS_1046013]® defined as:  
a) DLPA: Within the last 14 days (excluding Day 1), at 
least 9 days each with a minimum of 14 hours wear 
time; 
b) PAH -SYMPACT®: Of the [ADDRESS_1046014]® 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 21/[ADDRESS_1046015] part . 
EXCLUSION CRITERIA  1. PH Groups 2 –5 according to the updated clinical 
classification [Galiè 2015a ], and PAH Group [ADDRESS_1046016]  (i.e., PDE -5 inhibitor or sGC  
stimulator ). 
3. Patients treated with  prostacyclin, prostacyclin analog, or 
prostacyclin receptor agonist) at any time prior to Day  1 
(administration for vasoreactivity testing is permitted; 
previous prostacyclin / prostacyclin analogs used 
intermittently for the treatm ent of digital ulcers or 
Raynaud’ s phenomenon are permitted if stopped 
> 6 months prior to Day 1). 
4. Any hospi[INVESTIGATOR_763376] [ADDRESS_1046017] 6 months. 
8.
 Decompensated cardiac failure. 
9.
 Ongoing s ev ere arrhythmias.  
10. Cerebrovascular events (e.g., transient ischemic attack, 
stroke) within the last [ADDRESS_1046018] examination any time up to Visit 1 : 
a) Diffusing capacity of the lung for carbon monoxide 
< 40% of pr edicted UNLESS computed tomography 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 22/[ADDRESS_1046019] 2017 -000216 -42 
Doc No D -18.398  
 
reveals no or mild parenchymal  lung disease ; OR 
b) Forced vital capacity < 60% of predicted1; OR  
c) Forced expi[INVESTIGATOR_31737] < 60% of 
predicted1. 
13. Documented severe hepatic impairment (with or without 
cirrhosis) at Visit 1 , defined as Child -Pugh Class C. 
14. Documented severe renal insufficiency at Visit 1 , defined as 
estimated creatinine clearance < 30 mL /min, or serum 
creatinine > 2.5 mg/dL. 
15. Hemoglobin < 80 g/L (<  4.96 mmol/L) at Visit 1.  
16. Known or suspected uncontrolled hyperthyroidism. 
17. Known or suspected pulmonary veno -occlusive disease.  
18. Ongoing or planned dialysis. 
19. Body mass index above 40 kg/m2 at Visit 1 . 
20. Sitting systolic blood pressure below 90 mmHg at Visit 1. 
21. Treatment with a s trong inhibitor of CYP2C8 
(e.g.,  gemfibrozil) . 
22. Receiving or having received any investigational drugs 
within [ADDRESS_1046020] not be started during the course of the 
study. 
24. Concomitant life -threatening disease with a life expectancy 
of less than 12 months. 
25. Known hypersensitivity to any of the excipi[INVESTIGATOR_763377]. 
26. Pregnancy, breastfeeding, or intention to become pregnant 
dur
ing the study. 
27. Any factor or condition likely to impair  adherence to 
                                                 
1 Pulmonary function tests may be performed either with or without the use of bronchodilators, as per local clinical 
practice.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 23/[ADDRESS_1046021] 2017 -000216 -42 
Doc No D -18.398  
 
protocol mandated procedures , as judged by [CONTACT_1275] . 
STUDY TREATMENTS Investigational treatment  
Selexipag (ACT -293987) 200 mcg oral tablet twice daily 
(b.i.d.).  
Comparative treatment  
Matching placebo 200 mc g o ral tablet b.i.d . 
Study treatments will be provided as film -coated tablets in 
childproof bottles of 120 tablets. Store below 25 °C (77 °F). 
Keep the bottle tightly closed in order to protect from moisture. 
Individualized dose titration ( Weeks  1 to 12) 
Each patient should be  titra ted to the individualized HTD , 
which can range from [ADDRESS_1046022] dose 
in the evening. During dose titration some adverse reactions, 
reflecting the mode of action of the study treatment (such as headache, diarrhea, nausea and vomiting, jaw  
pain, myalgia, 
pain in extremity, arthralgia, and flushing), may occur. They 
are usually transient or manageable with symptomatic 
treatment. However, if a patient reaches a dose that cannot be tolerated  or managed
, the dose should be reduced to the 
previous dose level. In patients in whom up -titration was 
limited by [CONTACT_763393], a second attempt to continue up
-titration to the HTD up to a maximum dose of 1600 mcg 
b.i.d. may be considered until Week 12. 
Individualized maintenance dose ( Week s 13 to 24) 
The individualized maintenance dose is the HTD reached 
during individualized dose titration and should be maintained 
from  Week 13 to Week 24. Change of study treatment dose is 
allowed if needed for efficacy or safety/ tolerability reasons. If 
the therapy over time is less tolerated at a given dose, 
symptomatic treatment and/or a dose reduction to the next 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 24/[ADDRESS_1046023] 2017 -000216 -42 
Doc No D -18.398  
 
lower dose should be considered. The dose may be in creased 
(to a maximum dose of 1 600 mcg b.i.d.) if the patient may 
benefit from a higher dose, as judged by [CONTACT_093].  
ENDPOINTS Primary endpoints  
• Change from baseline to Week 24/EOT in actigraphy -
assessed DLPA  as measured by:  
o Daily time spent (minutes) in non -sedentary activity  
(> 100 activity counts per minute)  
o Percentage of daily time spent in non -sedentary activity 
(> 100 activity counts per minute)  
o Total DL PA in counts/min  
o Sleep: To tal sleep time ; minutes , wake after sleep onset ; 
minutes , number of awakenings, efficiency ( percentage)  
The study is designed as exploratory, and therefore all 
actigraphy variables are listed under primary endpoints. 
Secondary endpoints  
• Change from baseline to Week 24/EO T for following 
PAH -SYMPACT® domain scores: 
o Cardiovascular symptom domain score 
o Cardiopulmonary symptom domain score 
o
 Physical impact domain score  
o
 Cognitive/emotional impact d om ain score 
• Change from baseline to Week 24/EOT for following 
variables : 
o WHO FC  
o 6MWD 
o
 Borg dyspnea index at 6MWT  
o N-terminal pro b -type natriuretic peptide ( NT-proBNP ) 
Other endpoints  
• Change from baseline to Week 24/EOT for blood 
biomarkers associated with, e.g. , PAH worsening, right/left 
ventricle function, inflammation. 
• Association between actigraphy variables and other efficacy 
endpoints (PAH -SYMPACT®, 6MWD, etc.) 
Safety endpoints  
• Treatment -emergent AEs and serious AEs up to 30 days  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 25/[ADDRESS_1046024] 2017 -000216 -42 
Doc No D -18.398  
 
after study treatment discontinuation.  
• AEs leading to discontinuation of study treatment. 
• Change from  baseline in vital signs ( systolic and diastolic 
arterial blood pressure and pulse rate) and body weight from 
baseline to all assessed time points during the study. 
• Treatment -emergent marked laborator y abnormalities up to 
30 days after study treatment disc ontinuation. 
ASSESSMENTS  Refer to the schedule of assessments in  Table 1. 
STATISTICAL 
METHODOLOGY  All statistical analyses will be conducted by [CONTACT_763394]. A Statistical Analysis 
Plan (SAP) will provide full details of th e analyses, data 
displays, and algorithms to be used for data derivations. 
Analysis sets: 
The Screened Analysis Set includes all patient s who are 
screened and have a patient identification number. 
The Full Analysis Set (FAS) includes all patients randomly 
assigned to a study treatment. In order to adhere to the 
intention -to-treat principle as much as possible:   
• Patient s are evaluated according to the study treatment they 
have been assigned to (which may be different from the 
study treatment they have receiv ed), 
• All available data are included.  
The Per -protocol Analysis Set comprises all patient s who 
received study treatment and who complied with the protocol 
sufficiently to allow assessment of  the treatment effects. 
Criteria for sufficient compliance include  exposure to 
treatment, availability of measurements and absence of major protocol deviations that  have an impact on the treatment effect. 
The full list of criteria will be detailed in the SAP before 
making the full randomization information available.  
The Safety Set includes all patient s who received at least one 
dose of study treatment, and the analysis will be based on the actual  treatment received . 
Primary analysis : 
This study is designed as exploratory with the purpose to 
generate hypotheses on new end points. All analyses performed 
will be descriptive in nature with summary statistics and 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 26/[ADDRESS_1046025] 2017 -000216 -42 
Doc No D -18.398  
 
associated 95% confidence intervals (CI) provided when 
applicable.  Any p -value provided as result of a statistical model 
is to be considered as exploratory only.  
No adjustment for multiplicity will be performed.  There will be 
no interim analysis.   
All actigraphy  variables will be summarized by [CONTACT_763395] 
14 days: Baseline ( last [ADDRESS_1046026] dose) , Week 2 
(Day  1–14), Week 4 (Day 15–28), and so on until Week 24 
(Day 155–168) or EO T (last 14 days  period  on study treatment) 
in case of premature discontinuation. Any actigraphy data 
recorded after Day 168 /EOT  will not be considered in summary 
statistics and will be listed only.  
For all actigraphy variables  (continuous) , change from baseline 
to Week 24/ EOT will be analyzed (on the FAS) using an 
analysis of covariance including terms for treatment and region , 
and baseline values as covariates. The differences in least 
square means between treatment and placebo, correspo nding 2 -
sided 95% CI and p -value will be provided. 
All actigraphy variables will be also reported overtime with 
actual values, absolute change and percentage ch ange from 
baseline at each time point (14 days periods).  
Daily time spent and percentage of dai ly time spent will be also 
displayed according to activity categories “ sedentary ”, “light”, 
“moderate ”, “vigorous” and “ very vigorous ” based on the 
Freedson Adult algorithm [ Freedson 1998] . 
Secondary/exploratory analyses : 
PAH -SYMPACT® domain scores and others PAH -related 
variables ( 6MWD, Borg dyspnea index , NT -proBNP) will be 
analyzed similarly as actigraphy variables  (as conti nuous). 
WHO FCs will be described by [CONTACT_763396]. The association between actigraphy variables and others efficacy endpoints (PAH
-SYMPACT® domain 
scores, 6MWD, NT -proBNP) will be described using 
correlations, scatter plots  and regressions. Details will be 
provided in the SAP.  
Safety analysis:  
All safety analyses will be performed on the Safety Set using  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hyperten sion 
Protocol AC -065A404  
Version 2 
5 December 2018 , page 27/[ADDRESS_1046027] 2017 -000216 -42 
Doc No D -18.398  
 
descriptive statistics.  
Sample size : 
There are no longitudinal data available for actigraphy  
variables  in PAH patients. Therefore, the study is designed as 
exploratory and sample size is based on enrolment capabilities: 
100 patients will be randomized in total (50 in placebo group 
and 50 in s elexipag group).   
STUDY COMMITTEES  A Steering Committee has been appointed by [CONTACT_763397], the oversight of study 
conduct, the evaluation of results, and the support in 
publication. The committee is governed by a Steering 
Committee charter.  
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC-065A404  
Version 2 
5 December 2018 , page 28/[ADDRESS_1046028] 2017 -000216 -42 
Doc No D -18.398  
 
Table 1 Study periods, v isits at study site  and assessment s 
Telep hone calls from the study site to the patient and assessments  dur ing telephone calls are shown in Table 2.  
PERIOD  
(DURATION)  SCREENING  
(up to 14 days)  BASELINE  
(at least 14 
days)  TREATMENT  
(24 weeks)  FOLLOW -UP 
(30 days)  
VISIT  Number  1  2  3  4 U1, U2, …  P16 
 Name  [CONTACT_763440],  
ePRO period  Randomization1 ePRO period  Intermediate visit  ePRO period  End-of-
treatment  Unscheduled 
visits3 End-of-study 
telep hone call  
 Time  
(Time w indow)  Days  
−28 to  −15 Days  
−14 to  −1 Day  
1 Week 15  
Days  99 to 105 
(+3 days)  Week 16  
Day 113  
(−4 to + 7 days)  Week 23 
Days 155 to 161   
(+3 days)  Week 242 
Day 169  
(−4 to +14 days)  Any day between 
Day 1 and 
EOT+30 days  End-of-Treatment  
+30 days  
(+10 days)  
Informed consent4 X         
IRT interaction  X  X  X  X X11  
Eligibilit y X  X       
Demographics, PAH  X         
Medical hi story  X         
Prev./conc. therapi[INVESTIGATOR_014]  X  X5  X5  X5 X5 X5 
Vital sign s (BP, HR, body weight, 
height6) X  X  X  X X  
WHO FC  X  X  X  X X  
6MWT/Borg index  X    X  X X  
NT-proBNP, biomarkers  X13    X  X X  
Hematology, chemistry  X      X X  
Contraceptive methods used, 
pregnancy test7, [ADDRESS_1046029]®10   X  X  X    
Study treatment dose    X  X5  X5 X5, 11  
Study treatment dispensing/return   X  X  X X11  
AE and SAE12 X  X  X  X X X 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC-065A404  
Version 2 
5 December 2018 , page 29/[ADDRESS_1046030] 2017 -000216 -42 
Doc No D -18.398  
 
1) All assessments are to be done prior to first intake of study drug. 
2) In case of premature study treatment discontinuation, this visit with all assessments should be performed within 10 days after 
end-of-treatment, if possible.  
3) Unscheduled visits may be performed at any time during the study and may include all, some or additional assessments, based on the judgment of the investigator. Study assessments must be entered in the eCRF.  
4) Prior to any study mandated assessments. 
5) Only the changes are recorded.  
6) Height is measured at Visit 1  onl
 y. 
7) Serum pregnancy test s  performed by [CONTACT_82408] 1, Visit 3  (Week 16) and Visit 4  (Week 24).  
8) Urine pregnancy tests performed a t study site during Visit 2  and by [CONTACT_763398] 3 days prior to the telephone call  at 
EOT + 30 days. 
9) Actigraphy data are collected starting at Visit 1, uploaded by [CONTACT_701562], AND by [CONTACT_763399] .  
10) The PAH -SYMPACT® questionnaire is being completed daily during each of the 3 7 -day ePRO period s starting on Day −14, 
Day 99 (Week 15), and Day 1 55 (Week 23).  
11) An unscheduled visit is required for s tudy treatment dispensing  if dose is increased after Visit 3.  
12) All AEs and SAE s  that occur after signing the Informed Consent Form and up to [ADDRESS_1046031] be reported to Actelion drug safety on an SAE form. 
13) No sampling for blood biomarkers at re -screening , if collected at initial screening . 
 
6MWT, [ADDRESS_1046032]; AE, adverse event; BP, blood pressure; eCRF, electronic Case Report Form; EOT, end -of-treatment; 
ePRO, electronic patient -reported outcome; HR, heart rate; IRT, interactive response technology; NT -proBNP, N -terminal pro b -
type natriuretic peptide ; PAH, p ulmonary a rterial hypertension; PAH -SYMPACT®, Pulmonary Arterial Hy pertension Symptoms 
and Impact q uestionnaire; SAE, serious adverse event; WHO FC, World Health Organization functional class.  
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC-065A404  
Version 2 
5 December 2018 , page 30/[ADDRESS_1046033] 2017 -000216 -42 
Doc No D -18.398  
 
Table 2 Telep hone  calls from the study site to the patient, and assessments  
PERIOD S (DURATION)  TREATMENT  (24 weeks)  FOLLOW -UP 
(30 days)  Weeks 1 to 12  Weeks 13 to 24  Any time  
Telephone call  Number  P1 to P12  P13 P14 P15 UP1, UP2, …  P16 
 Name  [CONTACT_763441] 15 Week 20  Week 23  Unscheduled telephone call2 End-of-study telep hone call  
 Time  
(Time window)  Days 8, 15, 22, 29, 36, 43, 50, 57, 
64, 71, 78, 85  
(±3 days)  99 
(+3 days)  141 
(±3 days)  155 
(+3 days)  Any day between Day 1 and 
EOT+30 days  End-of-treatment  +30 days  
(+10 days)  
Conc. therapi[INVESTIGATOR_014]3 X X X X X X 
Contraceptive methods used3, 
urine pregnancy test4 Days 29, 57, [ADDRESS_1046034]®1  X  X   
Study treatment dose3 X X X X X  
AE and SAE5 X X X X X X 
 
1) PAH -SYMPACT® refers to reminding the patient of the start of the PAH -SYMPACT® assessment period . The call cannot be 
made earlier than the day indicated but can be postponed by a maximum of 3 days. 
2) Unscheduled telephone calls  may be performed at any time during the study and may include all, some or additional 
assessments, based on the judgment of the investigator. Study assessments must be entered in the eCRF. 
3) Only the changes are recorded.  
4) Urine pregnancy tests are performed  b y patient at home within 3 days prior to the telephone call s. 
5) All AEs and SAE s  that occur after signing the Informed Consent Form and up to [ADDRESS_1046035] be reported to Actelion drug safety on an SAE form. 
 
AE, adverse event; eCRF, electronic Case Report Form; EOT, end -of-treatment; PAH -SYMPACT®, Pulmonary Arterial 
Hypertension Symptoms and Impact Questionnaire; SAE, serious adverse event.  
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 31/[ADDRESS_1046036] 2017- 000216- 42 
Doc No D -18.398  
 
 PROTOCOL 
1 BACKGROUND 
1.1 Indication 
Pulmonary arterial hypertension (PAH) is a serious chronic disorder of the pulmonary 
circulation of diverse etiology and pathogenesis. PAH is characterized by a progressive increase in pulmonary artery pressure (PAP) and in pulmonary vascular resistance (PVR) potentially leading to right heart failure and death  [Benza 2010, Kylhammar 2014,  
Oudiz 2013] . The complex pathogenesis of PAH involves dysfunction of three key 
pathways: the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway [ Humbert 2004] . 
PAH is hemodynamically defined  as a resting mean pulmonary artery pressure (mPAP) 
of at least 25 mmHg with normal pulmonary artery wedge pressure (PAWP) (or left ventricular end  diastolic pressure [LVEDP]) of 15 mmHg or less, and a PVR greater than 
3 Wood Units (WU) [ Hoeper 2013].  
The updated clinical classification of pulmonary hypertension (PH) [Galiè 2015a ] 
classifies the numerous conditions that are known to lead or be associated with the development of PAH into [ADDRESS_1046037] of all, similar therapeutic approach.  
PAH may occur in the absence of a demonstrable cause (idiopathic), in a familial setting (heritable), as the result of the use of certain drugs and toxins, or it can be associated with a connective tissue disease, HIV infection, portal hypertension, conge nital heart disease, 
or schistosomiasis.  
1.2 Study treatment  
Uptravi® (Selexipag ) has been approved in the US and Europe for the indication of 
long-term treatm
ent of PAH. More detailed information on selexipag can be found in the 
Investigator’ s Brochure ( IB) [Selexipag IB ] 
1.2.[ADDRESS_1046038] 
active by [CONTACT_5071], selexipag is hydrolyzed to an active metabolite with prolonged terminal half
-life and a hi
gh selectivity for the prostacyclin receptor. Selexipag and its metabolite 
possess anti -fibrotic, anti -proliferative
, and anti -thrombotic activit
y. Oral selexipag is 
effective in an animal model of PAH, improving hemodynamic and structural factors leading to increased survival.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 32/[ADDRESS_1046039] 2017- 000216- 42 
Doc No D -18.398  
 
1.2.2 Clinical pharmacology 
For interactions as well as the pharmacodynamics and pharmacokinetics of selexipag , see 
the IB [Selexipag IB ]. 
1.2.3 Clinical efficacy  
In the mul
ticenter, double -blind, placebo -controlled, ev
ent-driven , Phas
e 3 clinical trial 
GRIPHON, conducted in 1156 patients with PAH, selexipag demonstrated  a clinically 
and statistically significant 40% risk reduction compared to placebo in the occurrence of 
a first morbidity/mortality event up to end -of-treatment (E
OT) (log-rank P  < 0.0001) 
[Sitbon 2015] . Res
ults of all supportive analyses on the primary endpoint were consistent 
with that of the main analysis, and the observed treatment effect was also consistent across subgroups (PAH etiology, region, ethnicity, gender, age, WHO functional class [FC], and baseline PAH background medication).  
The secondar
y endpoints of change from baseline to Week [ADDRESS_1046040] favoring selexipa g over placebo. The secondary endpoints 
of absence of worsening in WHO FC from baseline to Week 26 and of time to death of all causes up to study closure did not show a difference between selexipag and placebo [
Sitbon 2015] . 
1.2.[ADDRESS_1046041] frequently 
reported adverse events ( AEs) in the selexipag group were those associated with 
prostacyclin treatment: headache (65% vs 32% in placebo group), diarrhea (42% vs 
18%), nausea (33% vs 18%), jaw pain (26% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), and myalgia (16% vs 6%). A total of 43.8% and 47.1% of patients in the selexipag and placebo groups, respectively, had at least 1 serious adverse event  (SAE). The great majority of SAEs were consistent with the underlying PAH 
condition. PAH worsening and right ventricular failure were the most frequently reported SAEs, and both were reported at lower frequencies in the selexipag group (14.4% and 5.9%, respectively) compared to the placebo group (22.0% and 7.1%, respectively). A total of 31.7% of patients in the selexipag group and 37.1% in the placebo group had at least one AE leading to dis continuation of study treatment. Other than 
prostacyclin
-associa
ted AEs, most of the AEs that led to discontinuation of study 
treatment were SAEs associat ed with underlying PAH disease. 
Overall, i
n the GRIPHON study, the nature and incidence of typi[INVESTIGATOR_763378] -associa
ted AEs (i.e., headache, flushing, diarrhea, nausea, vomiting, jaw 
pain, myalgia and arthralgia) on selexipag was largely in line with that observed with prostacyclin and prostacyclin analogs [
Sitbon 2015] . 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 33/[ADDRESS_1046042] 2017- 000216- 42 
Doc No D -18.398  
 
Hypotension was reported more frequently in the selexipag group compared to the 
placebo group (5.9% and 3.8%, respectively). In the selexipag group, 9.7% of patients 
had systolic blood pressure (SBP) ˂ [ADDRESS_1046043] one occasion, compared to 
6.7% in the placebo group. A decrease from baseline of > 40 mmHg in SBP was reported for 2.3% and 3.0% of patients in selexipag and placebo groups, respectively. 
Bleeding was 
not observed more frequently in selex ipag-treated patient
s compared to 
placebo, including in those patients treated concomitantly with anticoagulants. Anemia was reported more frequently in the selexipag group and a small reduction in hemoglobin was observed at most post
-baseline visits.  
Hype rthyroidis
m was reported more frequently in the selexipag group compared to the 
placebo group. Corresponding laboratory changes were a small reduction in thyroid
-stimulating horm
one at most post -baseline visits.
 A possible association between 
thyroid disor ders and PAH is described in the literature [reviewed in  Marvisi 2013] . 
Pre
viously published investigations showed that prostaglandins may influence thyroid 
function by a direct effect on specific prostaglandin membrane receptors [ Chadha 2009] . 
1.[ADDRESS_1046044] in a real life, day -to-day 
setting. It is
 also recognized that no single measurement will adequately capture the 
aspects of disease and treatment from the point of view of and relevant to the patient. Such patient
-centered outcomes
 may play an important role in patient follow -up and 
treatment reimbu
rsement in the future.  
Actigraphy is
 a non -invasive method for
 the collection of information about the physical 
activity of patients in their real -life, day -to-day setting  [Godfrey 2008 ]. The technology
 
can be used for capturing objective information on sleep/wake behavior, circadian rhythm , and physical activity. Devices validated for the u se in clinical trials are available 
and allow for monitoring the adherence to proper wearing and handling. Actigraphy can provide insight s into the eff ect of an investigational therapy  on the patient ’s activity and 
mobility by [CONTACT_763400] ’s baseline activity and sleep behavior to their changes 
after the intervention. This allows assessing whether  the treatment has a positive impact 
on the exercise capacity of the patient. In contrast to other methods for assessing the exercise capacity of the patient (i.e. , [ADDRESS_1046045] [6
MWT] ) actigraphy allow s this 
assessment  to be performed in the  every -day environment  of t
he patient  [Mainguy 2011, 
Okum
us 2016, Pugh 2012, Ulrich 2012] . 
Patient -reported outcome (
PRO) is a method by [CONTACT_616216] ’s perceptions and 
experiences are collected by [CONTACT_2329] a questionnaire. The most widely used PRO for 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 34/[ADDRESS_1046046] 2017- 000216- 42 
Doc No D -18.398  
 
evaluating symptoms, functioning and quality of life (QoL)  in PAH clinical studies  is the 
Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)  [McKenna 2006 ]. 
In additi
on, other non -PAH speci
fic QoL questionnaires have been used previously in 
PAH studies. However, as these questionnaires were not developed specifically for use in 
PAH, they may not capture the aspects most important to patients with PAH and would not meet the FDA guidance requirements for a validated questionnaire [
FDA 2009 ]. 
PAH -SYMPACT® is a PAH specific PRO tool developed according to the FDA 
guidelines that allows the assessment of  PAH -specific S
YMptoms and their physical and 
cognitive/emotional impact [ McCollis
ter 2016] . 
The assessme
nts of daily life physical activity (DLPA) and PAH -SYMPACT® in a Phase 
4 clinical study with selexipag will provide patient -centered, re
al-world, and 
PAH -specific in
formation about the effects of selexipag on the daily life of patien ts with 
PAH. The additional assessment of objective clinical variables (i.e. , WHO FC, 6-minute 
walk d
istance [ 6MWD] ) may reveal their potential correlation with the patient’ s daily life 
experience and shed new light on disease mechanism.  
1.4 Summary of known and potential risks and benefits 
The study mandated procedures at site visits (i.e. , blood draw, 6MWT ) and wearing the 
actigrap hy device during the participation in the study do not pose a risk to the study 
participants. Given the extensive and long -term c ontrolle
d efficacy and safety data 
available with selexipag [ see Section  1.2] and the care
ful follow -up of patient s
 mandated 
by [CONTACT_3181]  (i.e., clinical examin ation, laboratory checks, week ly telephone calls 
during the titration phase of study treatment ), the benefit/risk  assessment supports the 
treatment of the patients  with selexipag  for the purpose of the current study. 
It is the inve
stigator ’s responsibility to monitor the risk -benefit ra
tio of study treatment 
administration, as well as the degree of distress caused by [CONTACT_763401], and to discontinue study treatment or the study if, on balance, 
he/she believ es that continuation would be detrimental to the patient s’ well
-being. 
[ADDRESS_1046047] of selexipag on DLPA  of patients with PAH.  
2.2 Secondary objectives 
• To e valuate the effect of selexipag on PAH symptoms and the impact on patients ’ 
daily life.  
• To e valuate the effect of selexipag on exercise capacity  and disease severity  in 
patients with PAH . 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 35/[ADDRESS_1046048] 2017- 000216- 42 
Doc No D -18.398  
 
• To evaluate the safety and tolerability of selexipag in patients with PAH . 
2.3 Other objectives 
• Explore potential association  between traditional efficacy outcomes and DLPA.  
• Explore the levels and level changes of biomarkers potentially associated with PAH. 
3 OVERALL STUDY DESIGN AND PLAN  
3.1 Study design  
This is a prospective, multi -cent er, double -bli nd, randomized, placebo -contr olled, 
parallel -group, 
exploratory Phase 4 study. 
Approx
imately 100 patient s will be randomized in a 1:1 ratio to either selexipag  or 
placebo . Treatment allocation will be stratified by  [CONTACT_11338] , i.e., Europe/ rest of the world vs 
North America . 
The study will be conducted in approximately [ADDRESS_1046049] 
enrollment.  
3.1.1 Study periods  
The study comprises the following consecutive periods: 
Screeni
ng period (duration up to 14 days): The period includes the informed consent 
process and assessments determining patient eligibility at Visit 1. Some of the assessments provide baseline data. At Visit [ADDRESS_1046050]® are given to the patient for outpatient use. Visit 2 defined as Day 1 is 
being scheduled. 
Basel
ine period  (duration at least [ADDRESS_1046051] 28 days):  The period starts at the 
end of Visit 1 and ends with randomization at Visit 2 on Day 1. The actigraphy device is 
worn for the entire period , 24 hours per day (except during charging ) for the collection of 
baseline DLPA . The recording of DLPA starts on the day of Visit 1. T he PAH -
SYMP
ACT® is assessed daily over a period of 7 days starting on Day − 14. The start of 
the PAH -SYMP
ACT® can be delayed until Day − 11, if the start on D ay −[ADDRESS_1046052]® are required for eligibility.  
Treat
ment p eriod  (duration 24 weeks):  For eligible patients with valid baseline data for 
DLPA and  PAH -SYMP
ACT®, the period starts on Day  1 (Visit 2) with confirmation of 
eligibility and randomization to one of the two double -blind
 treatment arms. Patients will 
receive the first dose of study treatment on Day  1. From Day  1 up to end of Week  12 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 36/[ADDRESS_1046053] 2017- 000216- 42 
Doc No D -18.398  
 
(Day  85) study treatment will be titrated to the highest individually tolerated dose. 
Patients will be called weekly by [CONTACT_763402], assess 
safety/tolerability, and support compliance with the actigraphy device. From Week  [ADDRESS_1046054] tolerated dose (HTD) is intended to be maintained 
(individual ized maintenance dose [IMD] ). Change of study treatment dose is allowed if 
needed for efficacy or tolerability reasons. An unscheduled visit is required for study 
treatment dispensing if dose is increased after Visit 3  (Week 16).  
Patients will co
ntinue to wear the actigraphy device during the whole [ADDRESS_1046055]® is assessed by [CONTACT_763390] (home, vacation, etc.). P atients will be called by [CONTACT_763403] -SYMPACT® assessment period  (Day 99 for Week 15 and Day 155 for Week 
23) and at Week 20, to  assess safety/tolerability, and to support compliance with the 
actigraphy device and the PAH -SYMPACT®. Visits at the study site are scheduled on 
Day 1 (Visit 2), Week 16/Day 113 (Visit 3), and Week 24/Day 169 (Visit 4). At Visit 4, 
study treatment is terminated (EOT). Upon premature discontinuation of study treatment 
prior to Week 24, the Visi t [ADDRESS_1046056]-treatmen
t safety f ollow- up period  (duration 30 days) : This period starts [ADDRESS_1046057] day of intake of study  drug. Patients will be followed up by 
[CONTACT_763404] s at investigator ’s discretion. The period is 
completed by [CONTACT_70705] -of-study (EOS
) tele phone call 30 days after EOT. This telephone 
call represent s the end of the patient’ s study participation.  
At any tim
e during the study, unscheduled tele phone calls or visits at the study site may 
be conducted if medically indicated at the discretion of the investigator. 
The visit sc
hedule and protocol -mandated ass
essments  are displayed in Table 1 and  
Tabl
e 2 and described in S ection s 7 and 8. 
The overall study design is depi[INVESTIGATOR_123614] [ Figure 1].  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 37/[ADDRESS_1046058] of recruitment (i.e., first Info rmed Consent Form [ICF] 
signed) and ends wi th the last visit of the last patient . Patient s will be treated for 
[ADDRESS_1046059] of selexipag on patient’ s 
DLPA. A placebo -contr
olled study design was chosen since s everal medication -
indepe
ndent factors may have an influence on DLPA, such as changes in duration of day 
light, w eather condition s, season, and motivational effect by [CONTACT_763405]. The placebo control will thus allow for the 
non-confounde
d evaluation of the treatment effect of selexipag on DLPA, but also on the 
patient  reported PAH symptoms and their impacts on daily life.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 38/[ADDRESS_1046060] 2017- 000216- 42 
Doc No D -18.398  
 
The use of placebo is considered safe and ethically justified because patients are required 
to be on background PAH therapy proven to be effective (Section 4.2).  
Selexipag is titra
ted to the patient’ s individualized HTD during 12 weeks as per the 
pi[INVESTIGATOR_22735] P hase 3 trial GRIPHON. Titration includes time periods during which the patient 
does not receive  the effective dose and/or experiences transient side effects . Both may 
affect DLPA  adversely . Therefore, a subsequent time period of additional [ADDRESS_1046061]® under conditions reflecting maintenance therapy.  
3.[ADDRESS_1046062] , the evaluat ion of  results, and the support in 
publication. The committee is governed by a Steering Committee charter.  
4 PATIENT POPULATION 
4.1 Patient population description  
This study will enroll adult male and female patient s aged 18 to 75 with Group I PH 
[Galiè 2015a ], except  subgroups 1.4.3 ( Portal hypertension) and  1.4.5 ( Schistosomiasis ), 
and except patients of subgroup 1.4.4 ( Congenital heart disease) with other than corrected 
simple congenital heart defects.  
Patient s must be in WHO FC II and III, stably treated with an endothelin receptor 
antagonist ( ERA ), and must have no significant pulmonary or cardiac concomitant 
diseases as detailed in Sections 4.[ADDRESS_1046063] Information  
(USPI ) and the EU Summary of Product Characteristics  (SmPC ) indication  for Uptravi®. 
Patient s with significant cardiovascular, pulmonary, immunological, hepatic, or 
ophthalmological medical conditions or therapi[INVESTIGATOR_763379], and/or their conditions could interfere with evaluation of the treatment e ffect, study assessment and interpretation of 
study results.   
To ensure an appropriate treatment for patient s assigned to placebo, a ll eligible patient s 
are required to be on background PAH therapy  with either an ERA or an ERA in 
combination with a drug ta rgeting the nitric oxide pathway  for at least [ADDRESS_1046064] 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 39/[ADDRESS_1046065] 2017- 000216- 42 
Doc No D -18.398  
 
demonstrated that an ERA either alone or in combination with a phosphodiesterase -5 
(PDE -5) inhibitor sign
ificantly reduces morbidity events in patients with PAH 
[Pulido 2013, Gal
iè 2015b ]. This evi
dence is not available for PDE -5 inhibitors a
nd 
soluble guanylate cyclase ( sGC) stimulators if administered as the only PAH specific 
therapy. Therefore, PDE -[ADDRESS_1046066] 3  months and on a stable dose for 30 
days prior to initiation of study drug.  
The safet
y and efficacy of selexipag in a pediatric population (< 18 years of age) have not 
been established. Patients above [ADDRESS_1046067] be fulfilled. It is not permitted to waive any of the criteria for any patient: 
1. Signed informed consent prior to initiation of any study mandated procedure. 
2. Male and female p atients with symptomatic PAH , aged from 18 years to 75 years 
inclusive. 
 A woman of childbearing potential [ see definition in Section 4.5.1] is eligible only if 
the following applies: 
a) Negative serum pregnancy test at  Screening Visit [ADDRESS_1046068] at randomization,  
AND  
b) Agreement to undertake monthly urine pregnancy tests during the study up to 30 days after study treatment discontinuation,  
AND  
c) Agreement to use an acceptable method  of contraception  [see definition in 
Section 4.5.2] from screening to 30 days after study treatment discontinuation. 
3. Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH  
according to the updated clinical classification [ Galiè 2015a ]:  
1.1. Idiopathic (IPAH)  
1.2. Heritable (HPAH)  
1.3. Drugs or toxins induced 
1.4. Associated (APAH) with one of the following: 1.4.1. Connective tissue disease  
1.4.2. Human immunodeficiency virus (HIV) infection 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 40/[ADDRESS_1046069] 2017- 000216- 42 
Doc No D -18.398  
 
1.4.4. Congenital heart disease with simple systemic -to-pulmonar y shunt (atrial 
septal defect, ventricular septal defect, patent ductus arteriosus) ≥ 1 year 
after surgical repair.  
4. Docum
ented hemodynamic diagnosis of PAH by [CONTACT_763406] (RHC). 
Prior to randomization the most recently performed RHC at rest showing: 
a) mPAP ≥  25 mmHg; and  
b) Rest
ing PVR ≥  240 dyn•s•cm-5 or 3 WUs ; and  
c) PAWP or L
VEDP ≤  [ADDRESS_1046070] 90 days and on a stable dose for 30 days prior to randomization. 
7. WHO
 FC II or III  at randomization . 
8. 6MWD ≥  100 m at Visit 1.  
9. Ability to walk without a walking a id. 
10. Vali
d baseline data at Visit 2 for DLPA and PAH -SYMPAC
T® defined as:  
a. DLPA:
 Within the last 14 days (excluding Day 1), at least 9 days each with a 
minimum of 14 hours wear time; 
AND  
b. PAH -SYMPAC
T®: Of the 7 -day PAH -SYMPAC T® assessment period, [ADDRESS_1046071] not fulfill  any of the following exclusion criteria. It is not permitted to 
waive any of the criteria for any patient : 
1. PH Groups 2–5 according to the updated clinical classification [ Galiè 2015a ], and 
PAH Group [ADDRESS_1046072] 
(i.e., PDE -5 inhibit or or sGC  stimulator ). 
3. Patients treated with prostacyclin, prostacyclin analog, or prostacyclin receptor agonist) at any time prior to Day 1 (administration for vasoreactivity testing is 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 41/[ADDRESS_1046073] 2017- 000216- 42 
Doc No D -18.398  
 
permitted; previous prostacyclin / prostacyclin analogs used intermittently for the 
treatm ent of digital ulcers or Raynaud ’s phenomenon are permitted if stopped  
> 6 months prior to Day 1). 
4. Any hospi[INVESTIGATOR_763376] [ADDRESS_1046074] 6 months. 
8. Decompensated cardiac failure. 
9. Ongoing s evere arrhythmias.  
10. Cerebrovascular events (e.g., transient ischemic attack, stroke) within the last [ADDRESS_1046075] 
examination  any time up  to Visit 1 : 
a) Diffusing capacity of the lung for carbon monoxide < 40% of predicted UNLESS computed tomography reveals no or mild parenchymal  lung disease ;  
OR 
b) Forced vital capacity < 60% of predicted
2;  
OR 
c) Forced expi[INVESTIGATOR_31737] < 60% of predicted2. 
13. Do
cumented severe hepatic impairment (with or without cirrhosis) at Visit 1 , defined 
as Child -Pugh C
lass C. 
14. Do
cumented severe renal insufficiency at Visit 1 , defined as estimated creatinine 
clearance < 30 mL /min, or serum creatinine >  2.5 mg/dL. 
15. Hemoglobin < 80 g/L (< 4.96 mmol/L) at Visit 1.  
16. Known or suspected uncontrolled hyperthyroidism. 
                                                 
2 Pulmonary function tests may be performed either with or without the use of bronchodilators, as per local clinical 
practice.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 42/[ADDRESS_1046076] 2017- 000216- 42 
Doc No D -18.398  
 
17. Known or suspected pulmonary veno -occlusi ve disease.  
18. Ongoin
g or planned dialysis. 
19. Body mass index ( BMI ) above 40 kg/m2 at Visit 1 . 
20. Sitting SBP  below 90 mmHg at Visit 1 . 
21. Treatment with a s trong inhibitor of CYP2C8 (e.g., gemfibrozil). 
22. Receiving or having received any investigational drugs within [ADDRESS_1046077] one of the following criteria:  
• Prev
ious bilateral salpi[INVESTIGATOR_1656], bilateral salpin go-oophorectom
y or hysterectomy. 
• Postm
enopausal (defined as 12 consecutive months with no menses without an 
alternative medical cause [ ICH M3 ]). 
• Premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis. 
The reason for not being of childbearing potential will be recorded in the electronic Case 
Report Form (e CRF ). 
4.5.[ADDRESS_1046078] study 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 43/[ADDRESS_1046079] be started from screening . The methods of 
contraception used (including non -pharmacol
ogical methods) must be recorded in the 
eCRF every [ADDRESS_1046080] one of the following methods is accepted  as reliable contraception:   
1. Oral, implantable, transdermal, or injectable hormonal contraceptives or intrauterine 
devices  with hormones;  
OR 
2. True abstinence from intercourse with a male partner only when this is in line with the preferred lifestyle of the patient ; 
OR 
3. Permanent female sterilization (tubal occlusion/ligation at least 6 weeks prior to screening) ;  
OR  
4. Steriliz
ation of the  male partner, with documented post -vasectom
y confirmation of the 
absence of sperm in the ejaculate.  
Rhythm m
ethods, use of a condom by [CONTACT_180487], use of a female condom or 
diaphragm alone are not considered acceptable methods of contraception for this study.  
5 TREATMENTS 
5.1 Study treatment  
Study treatments are selexipag  or placebo. Details and references are provided in Section 
1.2. 
5.1.1 Investigational treatm ent: Description and rationale  
• INN: Selexipag .  
• Formulation, strengths: Tablets of 200 micrograms (mcg) . 
• Route of administration: O ral (p.o.). 
• Dose: 200 mcg to 1600 mcg. Titration to the patient ’s individual HTD. 
• Regimen : One to 8 tablets twice daily (b.i.d.) (in the morning and in the evening). 
Exceptions from the twice daily dosing regimen are described in Section [IP_ADDRESS]. 
Dose, regimen, and titration scheme are in accordance with the IB for selexipag  
[Selexipag IB ]. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 44/[ADDRESS_1046081] 2017- 000216- 42 
Doc No D -18.398  
 
5.1.2 Matching placebo: Description and rationale 
• INN: Not applicable. 
• Formulation, strengths: Tablets of 200 mcg (matching appearance). 
• Route of administration: p.o. 
• Dose: 200 mcg to 1600 mcg. Titration to the patient ’s individual HTD. 
• Regimen: One to 8 tablets b.i.d. (in the morning and in the evening). Exceptions from 
the twice daily dosing regimen are described in Section [IP_ADDRESS].  
Dose, regimen, and titration scheme are in accordance with the IB for selexipag  
[Selexipag IB ]. 
5.1.[ADDRESS_1046082] increased dose in the evening. 
The tabl
ets should not be split, crushed or chewed, and are to be swallowed with water. 
[IP_ADDRESS] Individualized dose titration ( Weeks  1 to 12) 
Each pat
ient should be up -titrated to t
he individually HTD, which can range from 
200 micrograms given b.i.d. to 1600 micrograms given b.i.d. (individualiz ed maintenance 
dose [ IMD ]).  
The sta
rting dose is [ADDRESS_1046083] dose in the 
evening. During dose titration some adverse reactions, reflecting the mode of action of the stu dy treatment (such as headache, diarrhea, nausea and vomiting, jaw pain, myalgia, 
pain in extremity, arthralgia, and flushing), may occur. They are usually transient or manageable with symptomatic treatment. However, if a patient reaches a dose that cannot  
be tolerated, the dose should be reduced to the previous dose level.  
In pati
ents in whom up -titration w
as limited by [CONTACT_763407], a second attempt to continue up -titration 
t
o the H TD up to a maximum dose of 1600 mcg  b.i.d. may be considered until Week 12.  
For eve
ry dose change, t he end date of the previous dose and the start date of the new 
dose are recorded on a dedicated page in the e CRF.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 45/[ADDRESS_1046084] 2017- 000216- 42 
Doc No D -18.398  
 
A once -daily regimen ( 1 to 8 ta blets once in the morning or in the evening) is 
recommended in patients with moderate hepatic impairment (Child -Pugh cl
ass B) due to 
the increased exposure to selexipag and its active metabolite.  
In case
 of concomitant administration of a moderate inhib itor of CYP2C8 (e.g., 
clopi[INVESTIGATOR_7745], deferasirox, teriflunomide) the dosing frequency of selexipag/placebo should 
be reduced to once daily because of drug -drug inte
ractions. A drug -drug inte
raction study 
showed that clopi[INVESTIGATOR_763380] 2.7
-fold at ste
ady-state. The dosi
ng 
frequency should be reverted to twice daily when co -administra
tion of the moderate 
CYP2C8 inhibitor is stopped [ Selexipag
 IB]. 
In case of
 concomitant administration of a moderate inducer of CYP2C8 
(e.g.,  rifampi[INVESTIGATOR_2513]), dose adjustment of selexipag/placebo may be required because of 
drug-drug inte
ractions. Specifically, rifampi[INVESTIGATOR_763381] a relevant change in 
exposure to selexipag, whereas exposure to the active metabolite decreased by [CONTACT_2016] [
Selexip
ag IB ]. 
Table 3 Recommended d ouble -blind up- titration scheme  
Duration (Study Days)1 Dose regimen2, 3, 4 
Day 1 to Day 7 200 mcg  twice daily  (1 tablet twice daily)  
Day 8 to Day 14 400 mcg  twice daily  (2 tablets twice daily)  
Day 15 to Day 21 600 mcg  twice daily  (3 tablets twice daily)  
Day 22 to Day 28 800 mcg twice daily  (4 tablets twice daily)  
Day 29 to Day 35 1000 mcg twice daily  (5 tablets twice daily)  
Day 36 to Day 42 1200 mcg twice daily  (6 tablets twice daily)  
Day 43 to Day 49 1400 mcg twice daily  (7 tablets twice daily)  
Day 50 to Day  56 1600 mcg twice daily  (8 tablets twice daily)  
1 Duration is indicated to guide the recommended weekly up -titrat ion. Intervals may be prolonged based on 
tolerability considerations. The i ndividualized dose titration  should be completed no later than Day 85  
(Week 12) . 
[ADDRESS_1046085] dose within a period may be taken in the evening only, i.e., once a day.  
4 Exceptions from the twice daily dosing regimen are described in S ection [IP_ADDRESS] . 
[IP_ADDRESS] Individualized maintenance dose ( Week s 13 to 24) 
The IMD is the HTD reached during individualized dose titration and should be maintained from Week 13 to Week 24. Change of study treatment dose is allowed if 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 46/[ADDRESS_1046086] 2017- 000216- 42 
Doc No D -18.398  
 
needed for efficacy or safety/tolerability reasons. If the therapy over time is less tolerated 
at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered. The dose may be increased (to a maximum dose of 1600 mcg b.i.d.) if the patient may benefit from  a higher dose, as judged by [CONTACT_093] . For 
every dose change, t he end date of the previous dose and the start date of the new dose 
are recorded on a dedicated page in the eCRF.  
5.1.4 Treatment assignment  
At S
creening  (Visit 1) , patient s will be assigned a study -speci
fic subject number by [CONTACT_638619] (IRT) system. This number  consists of [ADDRESS_1046087] identifier. In case of re -scr
eening, the original number will also be 
used the second time.  
Afte
r having verified that the patient  meets all inclusion criteria and none of the exclusion 
criteria, the investigator/delegate contacts the I RT system  at Visit 2 to randomize the 
patient . The IRT assigns a randomization number to the patient  (in addition to the subject 
number mentioned above)  and assigns the treatment kit number s, which matches the 
treatment arm assigned by [CONTACT_400409].  The 
random ization list is generated by [CONTACT_763408], using IXRS 3.0. 
Patients will be randomized in a 1:1 ratio to either selexipag or placebo. Treatment 
allocation will be stratified by [CONTACT_11338], i.e. Europe/ rest of the world  vs. North America.  
5.1.5 Blinding  
This
 study will be performed in a double -blind f
ashion. The investigator and study 
personnel, the patient s, the Clinical Research Associates ( CRAs ), Actelion personnel, and 
CRO personnel involved in the conduct of the study will remain blinded to the study  
treatment until study closure. Actelion personnel responsible for clinical study supply distribution will need to be unblinded to ensure adequate supply of study treatment. These persons will be clearly identified, their unblinding will be documented in t he trial 
master file and they will not take part in any Clinical Trial Team (CTT) meetings after 
study set
-up h
as been completed.  
Until th
e time of unblinding for final data analysis, the randomization list is kept strictly 
confidential, and accessible only to authorized persons, who are not involved in the conduct of the study. 
The inve stigational treatment and its matching placebo are indistinguishable , and all 
treatment kits will be packaged in the same way.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 47/[ADDRESS_1046088] 2017- 000216- 42 
Doc No D -18.398  
 
5.1.6 Unblinding  
[IP_ADDRESS] Unblinding for final analyses 
Full randomization information will be made available for data analysis only after 
database closure, in accordance with Actelion Quality System (QS) documents. 
[IP_ADDRESS] Unblinding for interim analyses 
Not applicable. 
[IP_ADDRESS] Unblinding for suspected unexpected serious adverse reaction s 
If a suspected unexpected serious adverse reaction ( S[LOCATION_003]R ) occurs for a patient  
participating in the study, Actelion Global Drug Safety will request the unblinding of the 
treatment assignment. The treatment assignment will not be communicated to s ite 
personnel or to the Actelion CTT. Unblinded S[LOCATION_003]R information will be provided to respective health au thorities and independent ethics committees (IECs) or institutional 
review board ( IRBs ) only. S[LOCATION_003]Rs will be reported to investigators in a blinded fashion. 
[IP_ADDRESS] Emergency procedure for unblinding  
The investigator, study personnel and Actelion personnel must remain blinded to the patient ’s treatment assignment. The identity of the study treatment may be revealed only 
if the patient  experiences a medical event, the management of which would require 
knowledge of the blinded treatment assignment. In this case, the investigator can receive the unblinded treatment assignment through the IRT. In these situations, the decision to 
unblind resides solely with the investigator. Whenever it is possible, and if it does not interfere with or delay any decision in the best interest of the patient , the investigator is 
invited to discuss the intended unblinding with Actelion personnel. 
The occurrence of any unblinding during the study must be clearly justified and 
explained by [CONTACT_093]. In all cases, Actelion personnel must be informed as soon as possible before or after the unblinding. 
The circumstances leading to unblinding must be documented in the Investigator Site File 
(ISF) and eCRF.  
5.1.7 Study treatment supply  
Manufacture, labeling, packaging, and supply of study treatment will be  conducted 
according to Good Manufacturing Practice, Good Distribution Practi ce, Good Clinical 
Practice ( GCP ), and any local or national regulatory requirements . 
All study treatment supplies are to be used only in accordance with this protocol, and not for any other purpose. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 48/[ADDRESS_1046089] 2017- 000216- 42 
Doc No D -18.398  
 
[IP_ADDRESS] Study treatment packaging and labeling 
Study treatment is  provided as tablets and supplied in childproof bottles of 120 tablets. 
Study treatment is labeled to comply with the applicable laws and regulations of the 
countries in which the study sites are located. 
[IP_ADDRESS] Study treatment distribution and storage 
Study trea tment supplies must be kept in an appropriate, secure area and stored according 
to the conditions specified on the label. [IP_ADDRESS] Study treatment dispensing  
The p
atient s will receive sufficient study treatment to cover the period up to the next 
scheduled visit. Patient s are asked to return all used, partially used, and unused study 
treatment bottles at each vis it. The protocol -mandat
ed study -treatme
nt dispensing 
procedures may not be altered without prior written approval from Actelion. 
Once tr
eatment is assigned  to the patient as described in Section 5.1.4,  the IRT system 
allocates the treatment kit numbers  matching the treatment arm assigned by [CONTACT_763409],  for the titration period and start of maintenance period until W eek 16 .  
Likewise at Visit 3 (Week 16), the investigator/delegate contact s the IRT system which 
assigns the  treatment kit number s based on the patient’ s HTD for the maintenance period 
until Visit 4 (Week 24). The same process will be performed in IRT at  unscheduled visits in the specific dedicated 
module, for additional kit number assignment when applicable. An accurate record of the date and amount of study treatment dispensed to each patient  
must be available for inspection at any time.  
[IP_ADDRESS] Study treatment return and destruction  
On an ong
oing basis and/or on termination of the study, the CRA will collect used and 
unused treatment kits, which will be sent to the warehouse, where Actelion personnel or a 
deputy will check treatment reconciliation. In certain circumstances, used and unused study treatment containers may be destroyed at the site once study treatment accountability is finalized and has been checked by [CONTACT_208220], a nd 
written permission for destruction has been obtained from Actelion. The 
protocol
-mandat
ed study treatment return procedures may not be altered without prior 
written approval from Actelion. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 49/[ADDRESS_1046090] 2017- 000216- 42 
Doc No D -18.398  
 
5.1.8 Study treatment accountability and compliance with study treatment  
[IP_ADDRESS] Study treatment accountability  
The i
nventory of study treatment dispensed to and retur ned by [CONTACT_102]  
(i.e., study -tre
atment accountability) must be performed by [CONTACT_763410]. It  is to be recorded by [CONTACT_763411] -tre
atment dispensing and accountability log and in the e CRF, and 
checked by [CONTACT_215232]. The study treatment 
accountability log in the e CRF will include at least the following information for each 
study treatment unit (i.e ., bottle)  dispensed to the patient : 
• Di
spensed bottle  number 
• Date dispensed, and number of tablets dispensed (prepopulated in eCRF) 
• Date returned , and number of tablets  returned  
Eac
h medication bottle will have a label with a tear -off
 part specifying the study protocol 
number and the batch number. When the medication is issued to the patient, the investigator or pharmacist must remove the tear
-off pa
rt and affix it to the Drug 
Dispensing Log.  
All stu
dy treatment supplies, inc luding partially used or empty bottles must be retained at 
the site for review by [CONTACT_2689].  
If the patient  forgets to bring the remaining study treatment to a study visit, he/she must 
be instructed to not take any tablets from  the remaining study treatment bottle and to 
return it at the next visit.  
[IP_ADDRESS] Study treatment compliance 
Study tr eatment compliance is based on study treatment accountability . Study treatment 
compliance will be calculated at Visit 4/EOT  for the period between Vis it 3 and Visit  4 
using the below formula: 
Compliance = [(number of tablets  dispensed at Visit 3 − number of tablets  returned  at 
Visit 4) / Total number of tablets  that should have been taken during the period] ×  100. 
The number of tablets that should have been taken is derived from the HTD . 
Compliance is expected to be between 80% and 120%. Compliance values outside of this 
range will be considered as a protocol deviation .  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 50/[ADDRESS_1046091] time for the next scheduled dose (within approximately 6 hours).  
Study tr
eatment may be temporarily interrupted in respon se to an AE, a diagnostic or 
therapeutic procedure, a laboratory abnormality, or for administrative reasons. If study 
treatment is missed or interrupted for 3 days or more, study treatment should be re -started 
a
t a lower dose at the discretion of the investigator, and then titrated to HTD [Section 
[IP_ADDRESS]].   
If th
e dose is adjusted  or study treatment intake is interrupted  for more than 1 day  by [CONTACT_763412], she/he must immediately inform the investigator.  
Study treatment interruptions greater than [ADDRESS_1046092] lead to permanent 
discontinuation of study tre atment.  
5.1.10 Premature  discontinuation of study treatment  
The decis
ion to prematurely  discontinue study treatment may be made by [CONTACT_102] , the 
investigator, or Actelion personnel. The main reason and whether discontinuation of study treatment is the decision  of the patient  (e.g., tolerability
- or efficac
y-related),
 the 
investigator (e.g., due to pre -specifi
ed study treatment discontinuation criteria, an AE or 
lack of efficacy), or Actelion (e.g., study terminated) must be documented in the e CRF.  
A patient  has th
e right to discontinue study treatment at any time , without any 
justification , by [CONTACT_42909] (i.e., premature withdrawal from the study  [see Section  9.2]). 
Although a patient  is not obliged to give his/her reason for withdrawing from the 
treatment or the study, it is recommended that the investigator makes a reasonable effort to ascertain the reason(s), while fully respecting the patient ’s rights.  
The investigator must discontinue study treatment for a given patient  if, on balance, 
he/she believes that continued administration would be contrary to the best interests of the patient . 
Study -specifi
c criteria for discontinuation of study treatment are described in 
Section  5.1.11. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 51/[ADDRESS_1046093] a 30 -day saf
ety follow -up period aft
er EOT.  The 
period is completed by [CONTACT_763413]. This telephone call represents the end of 
the patient ’s study participation . 
A patient  
who prematurely  discontinues study treatment and withdraws consent to 
participate in any further study assessments is considered as withdrawn from the study. 
Withdrawal of consent must lead to permanent discontinuation of study treatment . 
Patient s who die or ar e lost to follow -up are a
lso considered as withdrawn from the study. 
Withdrawal from the study and follow -up medi
cal care of patient s withdrawn from the 
study is described in Sections  9.2 and
 9.4, respectively.  
5.1.11 Study -specific criteria for interruption / permanent  discont inuation of study 
treatment  
Study treatment interruptions exceeding [ADDRESS_1046094] lead to permanent discontinuation of study treatment. 
[IP_ADDRESS]  Hemoglobin abnormalities 
If ther
e is a decrease in hemoglobin from baseline3 of > 20 g/L during the treatmen t 
period, a re -test must b
e performed within 10  days, with additional laboratory evaluations 
that may include, but are not limited to, any of the following:  
• Red blood c
ell cellular indices (mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration), peripheral blood smear, 
reticulocyte count, iron status (iron level, serum ferritin, total iron binding capacity, transferrin saturation), lactate dehydrogenase, indirect bilirubin. 
Study treatment must be temporarily interr upted if clinically mandated based on the 
investigator ’s judgment, or in any of the following situations: 
• A decrease in hemoglobin to <  80 g/L (< 4.96 mmol/L),  
• A decrease in hemoglobin from baseline of >  50 g/L (> 3.10 mmol/L) , 
• The need for transfusion. 
Re-introduct
ion of study treatment may be considered by [CONTACT_208229], defined as a return of hemoglobin above the lower limit of the normal range or to baseline, is achieved.  
                                                 
[ADDRESS_1046095] intake of study treatment.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 52/[ADDRESS_1046096] 2017- 000216- 42 
Doc No D -18.398  
 
[IP_ADDRESS] Severe hepatic impairment 
If liver
 impairment is suspected, a clinical assessment of severity (e.g., Child -Pugh s
core) 
should be performed. If a severe hepatic impairment (e.g., Child -Pugh C)  is
 diagnosed, 
the study treatment must be discontinued.  
[IP_ADDRESS] Start
 of a CYP2C8 inhibitor 
Study treatment must be discontinued if a strong CYP2C8 inhibitor (e.g., gemfibrozil) is 
started.  
In cas
e of concomitant administration of a moderate inhibitor of CYP2C8 (e.g., 
clopi[INVESTIGATOR_7745], deferasirox, teriflunomide), the dosing frequency of selexipag/placebo 
should be reduced to once daily because of drug -drug int
eractions. A drug -drug 
inte
raction study showed that clopi[INVESTIGATOR_763382] 2.7 -fold at 
s
teady -state
. The dosing frequency should be reverted to twice daily when co 
administration of the moderate CYP2C8 inhibitor is stopped [ Selexi
pag IB ]. 
[IP_ADDRESS] Pregnancy 
If a female patient becomes pregnant while on study treatment, study treatment must be discontinued immediately, and a Pregnancy Form must be completed along wi th 
documentation on AE page in the e CRF [see Section  10.3].  
[IP_ADDRESS] Hyperthyroidism 
In the event of clinical suspi[INVESTIGATOR_763383], thyroid function 
markers including thyroid stimulating hormone, free triiodothyronine  (T3), and free 
thyroxine (T4) levels must be monitored by [CONTACT_093]/delegate and appropriate measures according to local clinical practice should be implemented.  
5.[ADDRESS_1046097] ing of
 previous/concomitant therapy 
The use of
 all study -concomi
tant therapy (including contraceptives and traditional and 
alternative medicines, e.g., plant -, animal -, or miner
al-based med
icines) will be recorded 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 53/[ADDRESS_1046098] be recorded in the e CRF if discontinued less than 
3 months prior to signing of the informed consent. The generic name, start/end dates of 
administration (as well as whether it was ongoing at start of treatment and/or EOS), route, 
dose, and indication will be recorded in the e CRF.  
5.2.3 Allowed concomitant therapy  
Sing
le-dose 
administration of a drug for vasoreactivity testing during RHC is allowed .  
Car
dio pulmonary rehabilitation programs based on ex ercise starting after Visit 4  
(Week  24) are allowed . 
5.2.4 Forbidden concomitant therapy  
Gemfibrozil, a strong CYP2C8 inhibitor, has been shown to increase the exposure of 
selexipag and its active metabolite significantly. Hence, concomitant administration of selexipag and strong inhibitors of CYP2C8 (e.g., gemfibrozil) is forbidden. 
Cardio pulmonary rehabilitation programs based on exercise ongoing or initiated at any 
time from 8 weeks prior to Visit 1 until Visit 4  (Week 2 4) are forbidden.  
5.2.5 Rescue therapy  
In th
e event of documented worsening of PAH, it is permitted to use prostacyclin, 
prostacyclin analogs, or prostacyclin receptor agonists as rescue therapy, in parallel to discontinuation of double
-blind s
tudy treatment. S tart of rescue therapy and 
discontinuation of double -blind s
elexipag or placebo may overlap in order to ensure 
sustained efficacy during the transition. Patient s starting rescue therapy remain in the 
study until EOS , i.e., Week 24/ EOT + 30 days. 
6 STUDY ENDPOINTS 
6.1 Efficacy endpoints 
6.1.1 Primary efficacy endpoint(s)  
The primary efficacy variables  are: 
• Cha
nge from baseline to Week 24/EOT in actigraphy -asses
sed DLPA  as measured 
by: 
– Da
ily time spent (minutes) in non -sede
ntary activity (> 100 activity counts  per 
minute)  
– Per
centage of daily time spent in non -sed
entary activity (> 100 activity counts per 
minute)  
– To
tal DLPA  in counts/min  
– Sleep:  Total sleep time (TST; minutes ), wake after sleep onset (WASO ; minutes ), 
number of awakenings, sleep efficiency ( percentage ) 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 54/[ADDRESS_1046099] 2017- 000216- 42 
Doc No D -18.398  
 
 
The study is designed as exploratory, and therefore all actigraphy variables are listed 
under primary endpoints. 
6.1.2 Secondary efficacy endpoints  
The secondary efficacy variables are:  
• Cha
nge from baseline to Week 24/EOT for following PAH -SYMP
ACT® domain 
scores:  
– Cardi
ovascular symptom domain score 
– Cardiopulmonary symptom domain score 
– Physical impact domain score  
– Cognitive/emotional impact domain score  
• Change from baseline to Week 24/EOT for following variables: 
− WHO FC  
− 6MWD 
− Borg dyspnea index at 6MWT  
− N-termin
al pro b -typ
e natriuretic peptide ( NT-pro
BNP ) 
6.1.3 Ot
her efficacy endpoints  
The other efficacy variables are:  
• Change from baseline to Week 24/EOT for blood biomarkers associated with, 
e.g., PAH worsening, right/left ventricle function, and inflammation. 
• As
sociation  between actigraphy variables and other efficacy endpoints  
(PAH -SYMP
ACT®, 6MWD, etc.). 
6.2 Safety endpoints  
The safety and tolerability endpoints are: 
• Tr
eatment -emerg
ent AE4 and SAEs  up to 30 days  after study treatment 
discontinuation. 
• AE
s leading  to discontinuation of study treatment. 
• Change from baseline in vital signs ( systolic and diastolic arterial blood pressure and 
pulse rate) and body weight from baseline to all assessed time  points during the 
study. 
                                                 
4 A treatment -em ergent AE is any AE temporally associated with the use of study treatment (from study treatment start  
until [ADDRESS_1046100] udy treatment discontinuation) whether or not considered by [CONTACT_42928].  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 55/[ADDRESS_1046101] 2017- 000216- 42 
Doc No D -18.398  
 
• Treatment -emergent m arked laborator y abn ormalities up to 30 days  after study 
treatment discontinuation.  
6.3 Biomarkers  
Based on nonclinical data [ Gomez -Arroyo 2015 ], it is hyp othesized that selexipag may 
have a beneficial effect on circulating biomarkers involved in right ventricular function 
and structure. Therefore, changes in such biomarkers from baseline to Week [ADDRESS_1046102] scientific evidence regarding right ventricular function and structure at the time of laboratory analysis. No genetic testing of any kind will be performed . 
7 STUDY ASSESSMENTS  
All study assessments will be performed by a qualified study staff member: medical, nursing, or specialist technical staff, and recorded in the eCRF, unless otherwise specified. Study assessments performed during unscheduled visits will also be recorded in the eCRF. Assessments will be performed  at the appropriate  visits or via telephone 
calls as indicated in the visit and assessment schedule s in Table 1 and Table 2
. If the 
pri
ncipal investigator (PI) delegates any study procedure/assessment for a patien t to an 
external facility, he/she should inform Actelion to whom these tasks are delegated. The set
-up and oversi
ght will be agreed upon with Actelion. The supervision of any external 
facilities remains the responsibility of the PI.  
Calibratio
n certificates for the temperature monitoring device for the study treatment 
storage area must be available prior to screening of the first patient  at the site . 
7.1 Patient characteristics 
During Visit 1, the following assessments are to be obtained and recorded in the eCRF.  
7.1.1 Informed consent signature (Visit 1)  
• Prior t
o any study -mandated
 procedures.  
• Origina
l ICF to be kept in the site file.  
• Date and time of informed consent signature [CONTACT_763442] . 
7.1.2 Demographics (Visit 1) 
• Age (in years).  
• Race (if allowed by [CONTACT_427] ) and Ethnicity. 
• Sex.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 56/[ADDRESS_1046103] 2017- 000216- 42 
Doc No D -18.398  
 
7.1.3 Documentation of PAH disease (Visit 1) 
• Date of diagnosis. 
• Etiology of PAH.  
• Most recent RHC: Date, mPAP (mmHg), PAWP (mmHg) or LVEDP (mmHg) if 
PAWP not available, PVR (WU). 
7.1.4 Medical history (Visit 1)  
• Chronic and acute medical conditions. 
• All previous medically important conditions. 
7.1.5 Previous and concomitant therapi[INVESTIGATOR_763384] (last dose, date of discontinuation) must be recorded in the eCRF if 
discontinued less than 90 days prior to informed  consent signature. 
• Concomitant medication start date, dose, route of administration, indication for which the medication is taken  are to be recorded  at Visit 1.  
• Changes to be recorded at site visits and telephone calls. 
7.1.6 Eligibility, randomization ( Visit 1  and Visit 2)  
Determination of eligibility: Eligibility criter ia [see Section 4
] are revi
ewed based on 
patient medical records, the assessments performed at Visit [ADDRESS_1046104]®.  
For pati
ents who fail screening, the following assessments must be performed if possible 
and recorded in the eCRF at Visit 1 and/or Visit 2: 
− Informed consent signature. 
− Demographics. 
− Reason for Screen failure.  
An eligible patient is considered randomized if  he/she is supplied with study treatment.  
7.[ADDRESS_1046105], which measures the distance covered by [CONTACT_763414] a 6 -minute wa
lk [Appendix 1
].  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 57/[ADDRESS_1046106] 2017- 000216- 42 
Doc No D -18.398  
 
At Visits 3 and 4, the 6MWT is performed at trough levels of study treatment. Trough 
level of  study treatment is defined as : the last dose has been taken not less than 8 hours 
prior to the 6MWT. 
Borg dyspnea index is assessed immediately after the 6MWT. Dyspnea is rated by [CONTACT_763415] 6MWT 
[Appendix 2 ]. 
7.2.2 WHO FC  
WHO FC will be assessed according  to Appendix 3.   
7.2.3 Daily life physical activity  
The DLP
A of the patient  is assessed via the actigraphy device ActiGraph GT9X Link . 
The device is given to the patient  at Visit 1 (Screening Visit), and the patient is instructed 
to wear the actigraphy device at the wrist of the non -dominant ha
nd (ambidextrous 
patient s may wear it at either wrist)  during the entire study up to Week 24. Patient  is 
instructed to upload data, i.e., epoch data, daily via the hand -held mobil
e device  (same 
device as used for the PAH -SYMPACT®) to the vendor’ s server  via a cellular 
connection. The submitted data will be used to monitor patient ’s compliance with device 
use and handling. Patient s will be provided with a paper manual .  
To ensure D
LPA data quality, t he epoch data received will be checked by [CONTACT_55899]. 
Should corrective actions be necessary, patient s may be contact[CONTACT_763416] (e.g., telephone call, text message) or via messages onto the hand -held mobil
e 
device from the vendor . At any time, the site and the CRA will have access to a patient  
report  displaying patient ’s adherence to DLPA assessment .  
The Acti
Graph GT9X Link  does  not display collected data, i.e., the patient s do not have 
access to their activ ity measurements since this could influence their behavior. At every 
site visit the study site transfers the complete data (raw data) from the ActiGraph GT9X 
Link to the vendor ’s server  as described in the site manual . The raw data will be 
transferred to Actelion Pharmaceuticals Ltd.  at the end of the study. 
Patient s must return the ActiGraph GT9X Link to the site  at EOT. The devices will be 
returned to the vendor . The patient is provided with a report (on paper) summarizing the 
patient ’s individual activity levels during his/her participation in the study.  
7.3 Safety assessments 
7.3.1 Vital signs  
• Sitting SBP and diastolic  blood pressure ( DBP ) (mmHg), measured ( always at the 
same arm ) after at least [ADDRESS_1046107] in a sitting position.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 58/[ADDRESS_1046108] 2017- 000216- 42 
Doc No D -18.398  
 
• Pulse rate (beats per minute), measured after at least [ADDRESS_1046109] in a sitting 
position. 
• Body weight (kg, lb).  
• Body height (cm, inch), at Visit 1 only. 
• BMI will be calculated and displayed automatically upon entry of weight and height in the eCRF . 
7.3.[ADDRESS_1046110] be reported on the Actelion Pregnancy form. 
7.4 Laboratory assessments  
7.4.1 Type of laboratory 
A central
 laboratory (see central laboratory manual for contact [CONTACT_8972]) will be used for all 
protocol -mandat
ed laboratory tests  (excluding urine pregnancy tests), including re -tests 
due
 to laboratory abnormalities and laboratory tests performed at unscheduled visits. 
Central laboratory data will be loaded into the clinical database, i.e., no entry  into the 
eCRF is required for central laboratory data.  
Eligibilit
y of patients at s creening may alternatively be determined using local laboratory 
tests as long as the central laboratory kit is used in parallel. Local laboratory results alone may be suffi cient in other exceptional situations (e.g., patient  is hospi[INVESTIGATOR_42868] a different 
hospi[INVESTIGATOR_174159] a medical emergency). Local laboratory data including the normal ranges must be entered on dedicated eCRF pages. The investigator/delegate will provide Actelion with the name, professional degree, and curriculum vitae  of the director of the 
local laboratory, a copy of the laboratory ’s certification, and the normal ranges for each 
laboratory test that is evaluated locally. These laboratory references must be u pdated 
whenever necessary.  
If a central laboratory sample is lost or cannot be analyzed, the investigator/delegate will collect an additional sample as soon as possible to repeat the analysis, unless a local laboratory sample was collected within the same time window and these test results are available.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 59/[ADDRESS_1046111] 2017- 000216- 42 
Doc No D -18.398  
 
Central laboratory reports will be sent to the study site. In the event of specific laboratory 
abnormalities (pre -define
d threshold values), the central laboratory will alert Actelion 
and the concerned stud y site.  
All labor
atory reports must be reviewed, signed and dated by [CONTACT_42920] 3  working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are considered clinically relevant or not. Clinically relevant laboratory findings that are known at the time of signing of informed consent must be recorded on the Medical History page of the e CRF. Any clinically relevant laboratory abnormalities detected after 
signing of informed consent must be reported as an AE or SAE as appropriate [see Section  10], and must be followed until the value returns to within the normal range or is 
stable, or until the abnormality is no longer clinically relevant.  
Details about the co llection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual.  
7.4.2 Laboratory tests 
The laboratory tests  performed are:   
• Hematology: basic panel . 
• Clinical chemistry : basic panel .  
• NT-proBNP . 
• Circ
ulating biomarkers involved in right ventricular function and structure: B lood 
samples will be collected at the central laboratory, shipped to Actelion at the end of 
the study, and stored at Actelion for up to [ADDRESS_1046112] patient ’s last visit and 
destroyed after that date. The list of biomarkers to be measured after the end of the study will be based on the latest scientific evidence regarding right ventricular function and structure at the time of laboratory analysis. No genetic test ing of any 
kind will be performed . 
• Pregnancy tests: see Section 7.6. 
• Thyroid function: Hyperthyroidism has been observed with selexipag . Thyroid 
function tests per formed locally are recommended as clinically indicated in the 
presence of signs or symptoms of hyperthyroidism . The test result and the normal 
range must be recorded in the eCRF . 
• Other laboratory assessments : Additional laboratory assessments will be done at the 
discretion of the investigator if deemed medically justified. Laboratory assessments and the respective normal ranges must be recorded as conventional units in the eCRF. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 60/[ADDRESS_1046113]® 
The PAH -SYMPACT® is a novel PRO developed according to the FDA guidance [ FDA 
2009] fo
r PROs specifically for patients with PAH.   
The PAH -SYMPACT® has two main parts: symptoms and i mpact [ Appendix 4] . T he 
symptom part is a questionnaire completed daily for [ADDRESS_1046114]® questionnaire should be filled out in the evening, at 
approximately the same time of each  day. If the start date of the collection period is 
missed, the PAH -SYMPACT® questionnaire can be started up to 3 days later. The 
questionnaire is administered  in local language via an e lectronic Patient -Reported 
Ou
tcome ( ePRO ) device ( hand -held mobile de
vice) that patients take home. Patient s will 
be trained on the ePRO device by [CONTACT_536601] 1 . Patient s will receive a 
paper patient  guide to take  home. Data will be transferred daily to an electronic database 
immediately upon completion of the questionnaire via a cellular connection to the 
vendor. T he data received will be checked for completion compliance.  
The site will b
e informed if the questionnaire has not been completed as per protocol . 
Should corrective actions be necessary, patient s may be contact[CONTACT_763416] (e.g., telephone call, text message) or via messages onto the mobile device from the 
vendor.  
At any time, th
e site and the CRA will have access to a web -based pati
ent report 
displaying patient ’s compliance b ased on the specifications list ed above for each day and 
summarized for each PAH -SYMPACT® data collection period. All ePRO data will be 
transferred to Actelion Pharmaceuticals Ltd at the end of the study.  
At EOT  patien
ts must  return the mobile device to the site.  The devices will be returned to 
the vendor. 
7.6 Additional assessments for women 
7.6.1 Childbearing potential  
The childbearing potential of a female patient will be assessed at Visit 1  and recorded in 
the eCRF . For definitions see Section 4.5.1. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 61/[ADDRESS_1046115] 2017- 000216- 42 
Doc No D -18.398  
 
7.6.2 Contraception  check  (women of childbearing potential only) 
The used method of contraception  will be recorded in the eCRF at Visit 1. Changes to the 
used method of contraception will be recorded at each visit and telephone call.  
7.6.3 Pregnancy tests  (women of childbearing potential only) 
Serum pregnancy test s for women of childbearing potential must be performed at 
Visits 1, 3, and 4. The test result will be recorded in the  eCRF . Urine pregnancy tests will 
be performed  at Visit [ADDRESS_1046116] 
be recorded in the patie nt’s medical record (source data). A serum pregnancy test is 
mandatory if pregnancy is suspected during the course of the study.  
8 VISIT SCHEDULE  
For each patient  there are 4 scheduled s tudy visits at the study site (Visits 1, 2, 3, and 4; 
see [Table 1]. For all visits, the patient s must be seen on the designated day with in the 
allowed time window as indicated  in Table 1. In case of p ermanent discontinuation of 
study treatment prior to Week 24, Visit 4, i.e., EOT V isit, must take place as soon as 
possible and no later than [ADDRESS_1046117] dose of study treatment , if possible.  
During the dose titration phase, i.e., up to Week 12, weekly telephone calls from the 
study site to the patient will be performed. During the dose maintenance phase, tele phone 
calls from the study site to the patient are scheduled at Week s 15, 20, and 23. There will 
be an EOS tele phone call from the study site to the patient 30 days after EOT [ Table 2]. 
Unscheduled site visits and telephone calls may be performed at  any time during the 
study.  
8.1 Site visits 
8.1.1 Visit 1: Screening/re- screening  
Screening starts with the signature [CONTACT_28513]. The patient is registered with the IRT system. The date on which the first s creening assessment is performed 
corresponds to the date of the Screening visit.  The visit includes the assessments as 
follows: 
• Informed consent 
• Demographics, PAH etiology 
• Medical history  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 62/[ADDRESS_1046118] 2017- 000216- 42 
Doc No D -18.398  
 
• Previous/concomitant therapi[INVESTIGATOR_014]  
• Vital signs ( blood pressure [ BP], heart rate [ HR], body weight, height) 
• WHO FC  
• 6MWT/ Borg dyspnea index  
• Ce
ntral laboratory tests: Hematology, clinical chemistry, NT -pro
BNP , biomarker s 
• Wom
en only: Assessment of childbearing potential  
• Women of childbearing potential only : Contraceptive methods used, serum pregnancy 
test 
• AE and SAE recording 
• Eligibility  
It is th
e responsibility of the investigator/delegate to obtain written informed consent 
from each patient  participating in this study after adequate face -to-fac
e explanation of the 
objectives, methods, and potential hazards of the study. The patient s who agree to 
participate in the study and the investigator/delegate must sign the ICF prior to any 
study -relat
ed assessment or procedure.  
Pati
ents who have signed informed consent  when the randomization target has been met 
may still be randomized.  
At Visit 1, t
he patient  is being equipped with, and trained on, the actigraphy device 
ActiGraph GT9X Link and the ePRO device ( hand -held m
obile device ). A paper manual 
is handed out to the patient. The patient ID is being registered within the application s for 
the ActiGraph and the mobile device on the vendors ’ internet platforms. Valid DLPA and 
PAH -SYMP
ACT® assessments performed between Visit 1 and Visit 2 are baseline 
assessments.  
It is
 permitted to re -scre
en patient s once, if the reason for non -elig
ibility was transient 
(e.g., abnormal laboratory test, invalid DLPA data, invalid PAH -SYMP
ACT® data). The 
rescreening visit must be performed within 28 days prior to randomization (Visit 2). 
At re -scr
eening, the informed consent process  and signature, and all Visit -1 asse
ssments 
need to be repeated, including NT -proB
NP, but excluding the sampling for blood 
biomarkers (unless not collected at initial screening).  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 63/[ADDRESS_1046119] 2017- 000216- 42 
Doc No D -18.398  
 
8.1.2 Visit 2: Randomization 
Visit [ADDRESS_1046120] 
study treatment dose (1  tablet of 200 mcg) at the site.  Study treatment is continued the 
following day, b.i.d. (morning and evening, preferably with food). the starting dose 
(200 mcg b.i.d.) of study treatment is recorded in the eCRF. 
The assessments ar e [see also  Table 1]:  
• Concomitant therapi[INVESTIGATOR_014] (changes only) 
• Vital signs (BP, HR, body weight) 
• WHO FC  
• Women of childbearing potential: Contraceptive methods used, urine pregnancy test 
• Eligibilit
y (including DLPA and PAH -SYMPACT® validity of baseline assessment)  
• AE and S
AE recording 
8.1.3 Visit 3: Intermediate Visit 
Visit 3 is p
erformed at Week 16 , Day 113 ( −4 to + 7 days) . Patient  adherence to DLPA 
assessment and PAH -SYMPACT® completion are reviewed. Actigraphy data are 
uploaded to the  vendor server . The patient should return any used and unused study 
treatment  to the site at this visit. Any change in study treatment dose is recorded in the 
eCRF. T he IRT system is used to assign study treatment supply to be dispensed to the 
patient.  
The assessm
ents are  [see also  Table 1]:  
• Concomitant therapi[INVESTIGATOR_014]  (changes only) 
• Vital signs (BP, HR, body weight) 
• WHO FC  
• 6MWT/Borg dyspnea index  
• Centr
al laboratory tests: NT -proBNP
, biomarker s, serum pregnancy test (w omen of 
childbearing potential) 
• Women of
 childbearing potential: Contraceptive methods used 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 64/[ADDRESS_1046121] 2017- 000216- 42 
Doc No D -18.398  
 
• Study treatment complian ce [see Section [IP_ADDRESS]]  
• AE and SAE recording 
8.1.4 Visit 4: End of treatment visit 
Visit 4 is performed at Week 24, Day 169 ( −4 to +14 days) . The visit must be scheduled 
at least 1 day after completion of the ePRO  period scheduled from Day  155 to Day 161. 
After premature study treatment discontinuation , Visit 4 is performed within 10 days 
after EOT , if possible . Actigraphy data are uploaded to the vendor server. The patient 
should return any used and unused study treatment to the site at this visit. The Actigraph  
GT9X Link and the mobile  device are returned to the site. The EOT  is indicated in the 
eCRF and entered in the IRT system. The patient is provided with a report (on paper) 
summarizing the patient’ s individual activity levels during his/her participation in  the 
study.  The dose of the last study treatment intake  is recorded in the eCRF.  
The assessments are  [see also Table 1]:  
• Concomitant therapi[INVESTIGATOR_014] (changes only) 
• Vital signs (BP, HR, body weight) 
• WHO FC  
• 6MWT/Borg dyspnea index  
• Centr
al laboratory tests: Hematology, clinical chemistry, NT -proBNP
, biomarker s, 
serum pregnancy test (women of childbearing potential). 
• Women of
 childbearing potential: Contraceptive methods used 
• AE and SAE recording 
The inves
tigator and the patient remain blinded towards the treatment assigned during the 
study (selexipag or placebo). If the patient and investigator decide to transition onto commercial selexipag (Uptravi
®), every effort will be made to avoid any interruptions in 
the treatment , recognizing that the patients will need to be re -uptitrate
d and the uptitration 
will be guided by [CONTACT_137021] . 
8.1.5 Unsche
duled visits  
Unscheduled visits may be performed at any time during the study. Depending on the reason for the unscheduled visit (e.g., AE), appropriate assessments will be performed based on the judgment of the investigator.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 65/[ADDRESS_1046122] continue according to the planned visit and assessment 
schedule.  
8.2 Telephone calls 
The schedule of telephone calls is shown in Table 2. 
8.2.1 Weekly telephone calls  up to Week 12  
Weekly (+/ −3 days) telephone calls from the study site to the patient will be performed 
starting 7 (+/− 3) days after Visit 2. The investigator or delegate  reviews the patient ’s 
compliance with the actigraphy device and the ePRO, and supports the patient in  
remain ing compliant , e.g., remind er to charge the ActiGraph  weekly . The investigator (or 
delegate) evaluates the tolerability of study treatment and guides its titration aiming at the HTD.  
The assessments are  [see also Table 2]: 
• Concomitant therapi[INVESTIGATOR_014] (changes only). 
• AE and SAE recording. 
• Study treatment dose changes.  
• Women of childbearing potential only: changes in contraceptive methods used . 
Patient  is asked to perform a urine pregnancy test at home at Weeks 4, 8, and 12 
(Days 29, 57, and 85) within [ADDRESS_1046123] day of 
Week 15  and Week 23 (Days 99 and 155)  and at Week 20 (Day 141) . The investigator or 
delegate reviews the patient ’s compliance with the actigraphy device and the ePRO, and 
supports the patient in remaining compliant, e.g., reminder to charge the ActiGraph 
weekly. The  patient  is reminded about the PAH -SYMPACT® assessment periods of 
Week s 15 and  23.  
The assessm
ents are  [see also  Table 2] : 
• Concomitant therapi[INVESTIGATOR_014] (changes only). 
• AE and SAE recording. 
• Study treatment dose changes.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 66/[ADDRESS_1046124] 2017- 000216- 42 
Doc No D -18.398  
 
• Women of childbearing potential  only: C hanges in contraceptive methods used. 
Patient  is asked to perform a urine pregnancy test at home within [ADDRESS_1046125] 30 days (EOT +30 days). The 
Post-Treatm
ent Safety Follow -up visit is
 conducted  by [CONTACT_756]  30 days (+ 10 days 
window) after EOT and represents the EOS  for the patient .  
The asse
ssments a re [see also  Table 1] : 
• Concomitant therapi[INVESTIGATOR_014] (changes only).  
• AE and SAE recording. 
• Women of childbearing potential only: changes in contraceptive methods used . 
Patient  is asked to perform a urine pregnancy test at home  within 3 days prior to the 
telephone call. 
8.2.4 Unscheduled telephone calls  
Unsche
duled telephone calls from the site to the patient may be performed at any time 
during the study  at the investigators discretion . In addition, unscheduled telephone calls 
may be required to support the patient  in adhering to DLPA assessment , 
PAH -SYMPAC
T® completion , and home urine pregnancy tests. 
[ADDRESS_1046126]-STUDY TREATMENT / 
MEDICAL CARE 
9.[ADDRESS_1046127] completed the study as per protocol. 
9.2 Premature withdrawal from study  
Patient s may voluntarily withdraw from the study without justification for any reason at 
any time. Patient s are considered withdrawn if they state an intention to withdraw further 
participation in all components of the study (i.e., withdrawal of consent), die, or are lost 
to follow -up. If a
 patient  withdraws consent, no further data will be collected in the  eCRF  
from  the date of withdrawal onward. The investigator may withdraw a patient  from the 
study (without regard to the patient ’s consent) if, on balance, he/she believes that 
continued participation in the study would be contrary to the best interests of the patien t. 
Withdrawal from the study may also result from a decision by [CONTACT_180505], including premature termination or suspension of the study. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 67/[ADDRESS_1046128] to follow -up (e.g.,
 document different ways of contact [CONTACT_42923], home address, email address, person to be contact[CONTACT_763417]). If the patient  cannot be reached, the site must make a 
reasonable effort to contact [CONTACT_102] , document all attempts, and enter the loss of 
follow
-up informa
tion into the  eCRF . The following methods must be used: a t least three 
telephone calls must be placed to the last available telephone number and one registered letter must be sent by [CONTACT_215253]. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., a visit by [CONTACT_763418] ’s home), respecting the patient ’s right to privacy. If the patient  is still 
unreachable after all contact [CONTACT_42927], he/she will be considered to be lost to follow
-up. 
If prem
ature withdrawal occurs for any reason, the reas on (if known) for premature 
withdrawal from the study, along with who made the decision ( patient , investigator, or 
Actelion personnel) must be recorded in the eCRF , if known. 
If for
 whatever reason (except death or loss -to-follow -up) a pat
ient is withdrawn  from the 
study, the investigator should make efforts to schedule a last appointment  / telephone call 
to assess the safety and well -being of t
he patient , collect unused study treatment and 
discuss follow -up medi
cal care. Data obtained during this last appointment / telephone 
call will be recorded in the patient s’ medical records but it will not be collected in the  
eCRF . The investigator must provide follow -up medi
cal care for all patient s who are 
prematurely withdrawn from the study, or must refer them for appropriate ongoing care, as described in Section 
9.4. 
9.3 Premature termination or suspension of the study  
Actelion reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
If the study is prematurely suspended or terminated, Actelion will promptly inform the 
investigators, the IECs/IRBs, and health au thorities, as appropriate, and provide the 
reasons for the suspension or termination. 
If the s
tudy is suspended or prematurely terminated for any reason, the investigator  – in 
agreement with Actelion – must promptly inform all enrolled patient s and ensure their 
appropriate treatment and follow -up, as desc
ribed in Section 9.4. Acte
lion may inform 
the investigator of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient s’ interests.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 68/[ADDRESS_1046129] promptly inform Acte lion personnel and the 
IEC/IRB, and provide both with a detailed written explanation of the termination or 
suspension. 
If the IEC/IRB suspends or terminates its approval  / favorable opi[INVESTIGATOR_23748], the 
investigator must promptly notify Actelion personnel and provide a detailed written 
explanation of the termination or suspension. 
9.4 Medical care of patient s after study completion / withdrawal from study 
After the patient ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to patient s what treatment(s) / medical care 
is necessary and available according to local regulations.  
The i
nvestigator and the patient r emain blinded towards the treatment (selexipag or 
placebo) assigned during the study (selexipag or placebo). If the patient and investigator decide to transition onto commercial selexipag (Uptravi
®) at the end of study treatment,  
every effort will be made to avoid any interruptions in the treatment , recognizing that the 
patients will need to be re -uptitr
ated and the uptitration will be guided by [CONTACT_137021] . 
[ADDRESS_1046130] medical occurrence, i.e., any unfavorable and unintended sign, including an abnormal laboratory finding, symptom, or disease that occurs in a patient  
during the course of the study, whether or not considered by [CONTACT_86190].  
A tre
atment -emer
gent AE is any AE temporally associated with the use of study 
treatment (from study treatment initiation until 30 days  after study treatment 
discontinuation) whether or not considered by [CONTACT_86190].  
AEs inc
lude: 
• Ex
acerbation of a pre -exis
ting disease.  
• In
crease in frequency or intensity of a pre -exis
ting epi[INVESTIGATOR_42861]. 
• Di
sease or medical condition detected or diagnosed during the course o f the study 
even though it may have been present prior to the start of the study. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 69/[ADDRESS_1046131] 2017- 000216- 42 
Doc No D -18.398  
 
• Continuous persistent disease or symptoms present at study start that worsen 
following the signing of informed consent. 
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or worsened during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, symptomatic or not, which was not present at study start or worsened during the course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment.  
• Overdose, misuse, abuse of the study treatment and study treatment errors. 
10.1.2 Intensity of adverse events  
The in
tensity of clinical AEs is graded on a three -poin
t scale – mild, moderate, severe – 
and is reported on specific AE pages of the eCRF . 
For AE
s not ongoing at the start of study treatment, i f the intensity of an AE worsens 
during study treatment administration, only the worst intensity should be reported on the AE page. If the AE lessens in intensity, no change in the severity is required to be reported. 
For AEs ongoing at the start of study treatment, if the intensity worsens after the sta rt of 
study treatment, a new AE page must be completed. The onset date of this new AE 
corresponds to the date of worsening in intensity. 
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the patient . It does not usually influence daily activities, 
and normally does not require intervention. 
 Moderate  
The event may make the patient  uncomfortable. Performance of daily activities may be 
influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort and usually interferes with daily activities. 
The patient  may not be able to continue in the study, and treatment or intervention is 
usually needed. 
A mild, moderate, or severe AE may or may not be serious [see Sec tion 10.2.1 ]. Th
ese 
terms are used to describe the intensity of a specific event. Medical judgment should be 
used on a case -by-case bas
is. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 70/[ADDRESS_1046132] be 
followed up until they are no longer considered cl inically relevant or until stabilization. 
The follow -up info
rmation obtained after the patient ’s EOS visit  / telephone call will not 
be collected by [CONTACT_180494].  
10.[ADDRESS_1046133] one of the 
following criteria:  
• Fatal.  
• Lif
e-thre
atening: Refers to an event in which the patient  was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have caused 
death had it been more severe.  
• Re
quiring in -patie
nt hospi[INVESTIGATOR_869]. 
• Re
sulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Me
dically significant: Refers to important medical events that may not immediately 
result in death, be life -thre
atening, or require hospi[INVESTIGATOR_42862], based upon appropriate medical judgment, they may jeopardize the patient , and may require medical or surgical intervention to prevent one of the 
outcomes listed in the definitions above. 
The f
ollowing reasons for hospi[INVESTIGATOR_42863]: 
• Hospi[INVESTIGATOR_180458], or social and/or conv enience reasons.  
• Hos
pi[INVESTIGATOR_5912] -planne
d (i.e., planned prior to signing informed consent) 
surgery or standard monitoring of a pre -exis
ting disease or medical condition that did 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 71/[ADDRESS_1046134] 2017- 000216- 42 
Doc No D -18.398  
 
not worsen, e.g., hospi[INVESTIGATOR_42865] a patien t with stable 
angina pectoris.  
However, complications that occur during hospi[INVESTIGATOR_42866] (e.g., if a 
complication prolongs hospi[INVESTIGATOR_059]). 
10.2.[ADDRESS_1046135] be re corded  on AE pages in the  eCRF  and reported on an SAE form  
to Actelion Global Drug Safety  (contact [CONTACT_180514]) , 
regardless of the investigator -att
ributed causal relationship with study treatment or 
study -mand
ated procedures. 
An SA
E is defined as related to protocol -mand
ated procedures if it appears to have a 
reasonable possibility of a causal relationship to either the study design or to 
protocol -manda
ted procedures. 
10.2.[ADDRESS_1046136] be 
followed up until resolution or stabilization, or until the event outcome is provided. The follow
-up infor
mation obtained after the patient ’s EOS visit  / telephone call must be 
reported to Actelion Global Drug Safety, but it is not recorded in the eCRF . 
10.2.4 Af
ter the [30 -day] follow- up period 
New S
AEs occurring after the [ADDRESS_1046137] be reported to Actelion 
Global Drug Safety within 24 hours of the investigator ’s knowledge of the event, only if 
considered by [CONTACT_763419].  
10.2.[ADDRESS_1046138] be reported by [CONTACT_763420] n 
24 hours of the investigator’ s first knowledge of the event.  
All SAEs must be recorded on an SAE form, irrespective of the study treatment received by [CONTACT_102] , and whether or not this event is considered by [CONTACT_341811].  
The SAE forms must be sent to Actelion Global Drug Safety (contact [CONTACT_42932]).  The investigator must complete the SAE form in English, and must 
assess the event ’s causal relationship to the study treatment.  
Any relevant i nformation from source documents regarding the SAE, e.g., hospi[INVESTIGATOR_42867], etc., must be summarized on the SAE form. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 72/[ADDRESS_1046139] also be reported within 
24 hour
s of receiving it. Actelion Global Drug Safety personnel ( or the CRO ’s drug 
safety personnel ) may contact [CONTACT_433051]. 
If th
e patient  is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_42869], it is the investigator ’s 
responsibility to contact [CONTACT_42933][INVESTIGATOR_42870] -rel
evant information and 
documentation. 
The ex
pectedness of an adverse reaction is determined by [CONTACT_763421] (RSI) section provided in the most recent version of the IB  and its 
Amendment 1. Any SAE  that is assessed as related and unexpected against the RSI is 
known as a S[LOCATION_003]R and must be reported by [CONTACT_215257] 
(including the EudraVigilance database if the study is conducted in Europe), IECs/IRBs and investigators. 
The f ol
lowing SAEs are commonly seen in patient s with underlying PAH disease and are 
therefore anticipated to occur in this patient  population. These SAEs (unless fatal) do not 
require expedited reporting to Health Authorities, ECs/IRBs, and investigators: symp toms of PAH worsening/exacerbation/ progression, abdominal pain, anorexia, chest 
pain, cyanosis, diaphoresis, dizziness, pre
-sync
ope, syncope, dyspnea, orthopnea, fatigue, 
hemoptysis, heart failure, hypoxia, palpi[INVESTIGATOR_814], collapse, systemic arterial hypote nsion, 
and tachycardia. Like all other SAEs, these SAEs must be reported on a n SAE form by 
[CONTACT_763422] 24 hours of the investigator ’s 
first knowledge of the event, and be reported on the AE form of the eCRF . 
10.[ADDRESS_1046140] counsel the patient  and discuss the risks of 
continuing with the pregnancy and the possible effects on the fetus. 
10.3.1 Reporting of pregnancy  
Irrespective of the treatment received by [CONTACT_102] , any pregnancy occurring after study 
start (i.e., signing of informed consent) up to [ADDRESS_1046141] be reported within 24 hours of the investigator ’s knowledge of the 
event.  
Pregnancies must be reported on the Actelion Pregnancy form, which is faxed to Actelion Global Drug Safety (see contact [CONTACT_42936]), and on an AE 
page in the eCRF . 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 73/[ADDRESS_1046142] be reported on an SAE form as described in 
Section  10.2.2. 
10.4 Study safety monitoring  
Study safety information (AEs, SAEs, laboratory values, vital signs, and study -speci fic 
examinations as required) is monitored and reviewed on a continuous basis by [CONTACT_208248] (in charge of ensuring patient s’ safety as well as data quality) . 
11 STATISTICAL METHODS 
All statistical analyses will be conducted by [CONTACT_763423].  
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, and algorithms to be used for data derivations. 
11.[ADDRESS_1046143] a patient  
identification number. 
11.1.2 Full Analysis Set  
The F
ull Analysis Set (FAS) includes all patient s randomly assigned to a study treatment. 
In order to adhere to the intention -to-treat p
rinciple as much as possible:  
• Pati
ents are evaluated according to the study treatment they have been  assigned to 
(which may be different from the stud y treatment they have received).  
• All available data are included.  
11.1.3 Per-protocol Ana lysis Set  
The Per -prot
ocol Analysis Set (PPS) comprises all patient s who received study treatment 
and who complied with the protocol sufficiently to allow assessment of  the treatment 
effects. Criteria for sufficient compliance include exposure to treatment , availability of 
measurements and absence of major protocol deviations that  have an impact on the 
treatment effect. The full list of criteria will be detailed in the SAP before making the full 
randomization information available. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 74/[ADDRESS_1046144] one dose of study treatment, and 
the analysis will be based on the actual  treatment received . 
11.1.5 Usage of the analysis sets  
The primary  efficacy  analysis will be performed  on the FAS  based  on treatment as  
randomized. Secondary and other efficacy analyses will also be performed on the  FAS. 
The PPS will be used for sensitivity analyses  for primary efficacy variables . 
Safety analyses will be performed on the Safety Set based on treatment as received.  
Patient  listings will be based on the FAS , unless otherwise specified. Patient  disposition 
will be described for the Screened Analysis Set.  
11.2 Variables 
All variables described thereafter are related  to the endpoints defined in Section 6. 
11.2.1 Primary efficacy variables 
The primary efficacy variables are:  
• Chang
e from baseline to Week 24/EOT in actigraphy -assess
ed DLPA  as measured 
by: 
– Dail
y time spent (minutes) in non -sedent
ary activity (> 100 activity counts  per 
minute)  
– Percen
tage of daily time spent in non -sede
ntary activity (> 100 activity counts per 
minute)  
– Tota
l DLPA  in counts/min  
– Sleep: TST ( minutes ), WASO  (minutes ), number of awakenin gs, efficiency 
(percentage ) 
Furthers details on other actigraphy variables will be provided in the SAP. 
11.2.2 Secondary  efficacy variables  
The secondary efficacy variables are:  
• Chang
e from baseline to Week 24/EOT for following PAH -SYMPAC
T® domain 
scores:  
– Car
diovascular symptom domain score 
– Cardiopulmonary symptom domain score 
– Physical impact domain score  
– Cognitive/emotional impact domain score  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 75/[ADDRESS_1046145] 2017- 000216- 42 
Doc No D -18.398  
 
• Change from baseline to Week 24/EOT for following variables: 
− WHO FC  
− 6MWD 
− Borg dyspnea dyspnea index  at 6MWT  
− NT-proBN
P 
11.2.3 Oth
er efficacy variables 
The other efficacy variables are:  
• Change from baseline to Week 24/EOT for blood biomarkers associated with, 
e.g., PAH worsening, right/left ventricle function, and inflammation. 
• Ass
ociation between actigraphy variables and other efficacy endpoints 
(PAH -SYMPAC
T®, 6MWD, etc.). 
11.2.4 Safe
ty variables  
Safety variables are listed in Section  6.2. 
An AE
 is defined as any event  that is recorded on the AE  eCRF  module regardless of the 
onset date.  Treatment -emerg
ent events are those with onset date/time ≥ start date/time of 
study treatment and up to 30 days after EOT . 
Labor
atory analyses are based on data received from the central laboratory. All 
transferred central laboratory data are taken into account regardless of whether they 
correspond to scheduled or unscheduled assessments. 
11.3 Description of statistical analyses 
11.3.1 Overall testing strategy  
This s
tudy is designed as exploratory  with the purpose to generate  hypotheses on new  
endpoints . All analyses  performed  will be descriptive with summary statistics and 
associated 95% confidence intervals (CI) provided when applicable . Any p -value 
pr
ovided as result of a  statistical model is to be considered as exploratory only.  
No ad
justment for multiplicity will be performed.  
11.3.2 Analysis of the primary efficacy variables 
All actigraphy  variables will be summarized by [CONTACT_763395] 14 days: Baseline (last [ADDRESS_1046146] dose), Week 2 (Day 1 –14), Week 4 (Day 15–28), and so on until Week 24 
(Day 155–168) or EO T (last 14 days  period on study treatment) in case of premature 
discontinuation. Any actigraphy data recorded after Day 168 /EOT  will not be considered 
in summary statistics and will be listed only.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 76/[ADDRESS_1046147] 2017- 000216- 42 
Doc No D -18.398  
 
[IP_ADDRESS] Hypotheses and statistica l model 
As the study is designed as exploratory, no formal hypothesis will be tested .  
For all a
ctigraphy variables  (continuous) , change from baseline to Week 24/ EOT will be 
analyzed using an analysis of covariance (ANCOVA) including terms for treatment and 
region , and baseline values as covariates. The differences in least square means between 
treatment and placebo, corresponding 2 -sided 95%
 CI, and p -value 
will be pr ovided. 
All actigr
aphy variables will be also reported overtime with actual values, absolute 
change and percentage change from baseline at each time point (14 days periods).  
Daily time spent and percentage of daily time spent will be also displayed according to 
activity categories “sedentary ”, “light”, “moderate”, “vigorous” and “ very vigorous ”. The 
different intensity levels (cut points) ranging from sedentary to very vigorous are based on the Freedson Adult algorithm  [Freedson 1998] : “Sedentary ” (0–99 counts/ min), 
“Light ” (100–1951 counts/ min), “Moderate ” (1952–5724 counts/ min), “Vigorous” 
(5725–9498 counts/min) and “Very Vigorous” (9499 + counts/m in). 
[IP_ADDRESS] Handling of missing data  
To be considered evaluable for a given time , actigraphy variables should have been 
measured for at least  7 complete days (consecutive or not) at a specific time period of 
assessment (baseline, Week 2, …, Week 24/ EOT). A complete day is define d as a record 
of at least [ADDRESS_1046148] time  period  available at Week 24/ EOT evaluation  
(last observation carried forward) . Further details  will be provided in the SAP.  
[IP_ADDRESS] Main analysis 
All actigraphy variables will be analyzed in same way  on the FAS population using the 
model and summary statistics described in Sectio n [IP_ADDRESS]. 
[IP_ADDRESS] Supportive/sensitivity analyses  
Supportive analyses based on the PPS will be provided. In addition, repeated measures 
mixed models will be used to evaluate the effect of s elexipag relative to placebo over 
time.   
Further supportive analyses will be described in the SAP.  
[IP_ADDRESS] Sub-group analyses 
Subgroup analyses will be performed  at least by [CONTACT_11338] (randomization stratification 
factor) . Additional subgroups analyses will be described in the SAP.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 77/[ADDRESS_1046149] 2017- 000216- 42 
Doc No D -18.398  
 
11.3.3 Analysis of secondary efficacy variables  
All secondary analyses will be performed on the FAS. 
[IP_ADDRESS] PAH -SYMPACT® 
All PAH -SYMPACT® domain scores (cardiovascular symptom domain score, 
cardiopulmonary symptom domain score, physical impact domain score, 
cognitive/emo tional impact domain ) will be reported as continuous variables over time 
with actual values, absolute change and percentage change from baseline at each time points.  
For cha
nge from baseline to Week 24/ EOT , the same analysis as for primary variables 
(ANCOVA described in Sectio n [IP_ADDRESS] ) wil
l be performed for the [ADDRESS_1046150]® 
domain scores. 
Furthe
r details will be provided in the SAP.  
[IP_ADDRESS] Others PAH related clinical outcomes  
Others PAH related variables ( 6MWD, Borg dyspnea index) will be reported over  time 
with actual values, absolute change and percentage change from baseline at each time  
points.  
For change from basel ine to Week 24/ EOT , the same analysis as for primary variables 
(ANCOVA described in Sectio n [IP_ADDRESS])  will be performed for 6MWD and Borg 
dyspnea index.  
WHO FCs will be d
escribed by [CONTACT_763424]. NT -proBNP
 
will be described by [CONTACT_763425]. In addition, c hange from baseline to 
Week 24/ EOT  in NT -proBNP (
log-transf
ormed) will be analyzed  using an ANCOVA 
with factors for treatment group, region , and a  covariate for baseline NT -proBNP
  
(log-trans
formed).   
[IP_ADDRESS] Assoc
iation between actigraphy and others efficacy endpoints 
The ass
ociation  between actigraphy variables and others efficacy endpoints  
(PAH -SYMPACT® domai n scores, 6MWD, NT -proBNP ) will be described using 
correlations, scatter plots and regressions. Details will be provided in the SAP.  
11.3.4 Analys
is of the safety variables  
All safety analyses will be performed on the Safety Set using descriptive statistics. All  
safety  data will be listed, with flags for quantitative abnormalities. AEs in patient s who 
were screened but not randomized will be listed.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 78/[ADDRESS_1046151] 2017- 000216- 42 
Doc No D -18.398  
 
[IP_ADDRESS] Adverse events  
A tre
atment -emer
gent AE is any AE temporally associated with the use of study 
treatment.  The number and percentage of patient s experiencing treatment  emergent AEs 
and SAEs at least once will be tabulated by [CONTACT_180526]:  
• Me
dical Dictionary for Regulatory Activities (MedDRA ) system organ class (SOC) 
and individual preferred term within each SOC,  in descending order of incidence.  
• Frequency of patient s with events coded with the same preferred term, in descending  
order of incidence.  
Fur
thermore, treatment -eme
rgent AEs and SAEs will be tabulated as described above by  
[CONTACT_1037] r elationship to  study treatment.  
AEs
 leading to premature discontinuation of study treatment and AEs with  outcome death 
will be summarized as described above.   
Listings will be provided for all reported AEs, including SAEs. In addition, separate  
listings will be provide d for SAEs, for AEs leading to premature discontinuation of study  
treatment, and for AEs with outcome death. 
For AEs occurring more than 30 days after discontinuation of the study  treatment, a 
dedicated analysis will be described in the SAP.  
[IP_ADDRESS] Laboratory variables 
Descriptive summary statistics by [CONTACT_763426], in both hematology and blood chemistry  
laboratory tests. In order to minimize missing data and to allow for unscheduled visits, all  
recorded assessments up to EOT plus [ADDRESS_1046152] fitting time window for that assessment.   
Actelion internal guidelines will be  used for the definitions of marked abnormalities and  
for the standardization of numeric values obtained from different laboratories and/or  
using different normal ranges. Standard numeric laboratory variables are transformed to  
standard units. All laboratory data transferred are taken into account regardless of  
whether they correspond to scheduled (per protocol) or unscheduled assessments. Marked laboratory abnormalities will be summarized for each laboratory variable by  
[CONTACT_180528]. Absolute values a nd changes  
from baseline of laboratory values during the course of the study will be summarized 
using the usual location and scale summary statistics by [CONTACT_1570].  
The num
ber and percentage of patient s with treatment -emer
gent laboratory abnormalities  
will be tabulated by [CONTACT_1570]. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 79/[ADDRESS_1046153] 2017- 000216- 42 
Doc No D -18.398  
 
[IP_ADDRESS] Vital signs and body weight 
Vital s
igns (BP, pulse rate), and body weight will be summarized at each study visit using 
summary statistics by [CONTACT_763427]. Patient s for whom no post -basel
ine value is available are excluded from the 
analysis of the changes from baseline in the Safety Set.  
11.3.5 Ex
posure to study drug  
Exposure to study drug will be described in terms of duration, HTD (defined as the dose 
at Week 12) and IMD  (defined as the dose to  which a patient  was exposed for the longest 
duration during the maintenance period).  
The duration of exposure is defined as the time elapsing between the study  drug initiation 
and discontinuation, inclusive. The exposure time will be tabulated by  [CONTACT_763428], median, standard deviation (SD), first and third quartiles,  minimum and 
maximum. The cumulative distribution of exposure time by [CONTACT_763429]. Count 
and percentages of patients within each HTD and IMD dose class will be tabulated by 
[CONTACT_2948]. 
11.3.6 Baseline characteristics and concomitant medications  
Continuous baseline variables  and disease characteristics (e.g., age, height, weight,  BMI, 
BP, pulse rate, 6MWT, Borg Dyspnea index and time from PAH  diagnosis) will be 
summarized by [CONTACT_18672], median, SD , first and third quartiles, 
minimum and maximum. Qualitative baseline variables  and disease characteristics ( e.g., gender and race, etiology  
of PAH, WHO FC , medical history, previous and concomitant medications)  will be 
summarized by [CONTACT_95006]. Individual patient listings 
will be provided by [CONTACT_1570]. 
Previous and concomitant medications will be coded according to the latest available  
version of the WHO drug code and the anatomic therapeutic  chemical class code. They 
will be summarized by [CONTACT_24975] (i.e., previous and concomitant) and treatment group by 
[CONTACT_763430].  
11.4 Interim analyses 
Not applicable.  
11.5 Sample size  
There are no longitudinal data available for actigraphy  variables  in PAH patients . 
Therefore  the study is designed as exploratory and the sample size is based on enrolment 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 80/[ADDRESS_1046154] 2017- 000216- 42 
Doc No D -18.398  
 
capabilities: 100 patients will be randomized in total (50 in placebo group and 50 in 
selexipag group).  
One of t h
e primary variables is the difference between the two  groups for the change 
from baseline to Week24/ EOT for the number of daily minutes spent in non -sedent
ary 
activity. A number of 100 patients will provide an acceptable precision for associated width of 95% CI (assuming normal distributions) given scenarios of common SD ranging  
from 30 to 90 minutes [
Table 4
 below]. Calculations were made using software FAST 
version 4. 
Table 4 Confidence interval (2 -sided 5%) width assuming different scenarios 
of SD  
Common SD for change from baseline in 
time spent (minutes) in non -seden
tary 
activity  Confidence interval (2 -sided 5% ) width for difference 
between two groups for time spent (minutes) in non -
sedentary activity  
30 ± 11.76  
40 ± 15.68  
50 ± 19.6 
60 ± 23.52  
70 ± 27.44  
80 ± 31.36  
90 ± 35.[ADDRESS_1046155] deviation . 
Those CI widths are indicative only, and the main analysis for actigraphy variables  will 
be based on ANCOVA including terms for treatment and region , and baseline values as 
covariates.  
12 DATA HANDLING 
12.1 Data collection 
The investigator/delegate is responsible for ensuring the accuracy, completeness and 
timelines of the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of the data.  Data reported in the  eCRF  
derived from source documents must be consistent with the source documents. 
eCRF d
ata will be captured via electronic data capture (using the Rave system  provided 
by [CONTACT_70598], Inc, a web -based tool ). The i nvestigator and site personnel will be 
trained to enter and edit the data via a secure network, with secure access features (username, password, and identification – an electronic password system). A complete 
electronic audit trail will be maintained. The investigator/d elegate will approve the data 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 81/[ADDRESS_1046156] 2017- 000216- 42 
Doc No D -18.398  
 
(i.e., confirm the accuracy of the data recorded) using an electronic signature (ref. to US 
21 CFR Part 11). 
Entr
ies recorded by [CONTACT_763431] -SYMPA
CT® questionnaire are considered 
source data. Site personnel will rev iew and ensure completeness of the patient s’ entries.  
Pati
ent screening and randomization data will be completed for all patient s (i.e., eligible 
and non -elig
ible) through the IRT system and  eCRF . 
For
 each patient  who enters the screening period of the study , an eCRF  must be 
completed and signed by [CONTACT_093]/delegate. If a patient  withdraws from the study, 
the reason must be noted on the eCRF . 
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On the 
eCRF  or other documents (e.g., documents attached to SAE forms / Pregnancy forms) 
submitted to Actelion and any CROs, patient s must be identified only by [CONTACT_259175], date of birth, hospi[INVESTIGATOR_42871], or any othe r identifier. 
The investigator/delegate must keep a patient  identification code list at the site, showing 
the screening/randomization number, the patient ’s name, date of birth, and address or any 
other locally accepted identifiers. Documents identifying th e patient s (e.g., signed ICFs) 
must not be sent to Actelion, and must be kept in strict confidence by [CONTACT_093]/delegate.  
The external service provider for actigraphy (ActiGraph) will not have access to personally identifiable patient information. The external service provider for the ePRO  
(ExcoIntouch) can receive personally identifiable information (private mobile phone number) if the patient agrees to this. This information is used to send study related 
messages (sent by [CONTACT_763432]) to the patient ’s private mobile phone. However, 
ExcoIntouch is obliged to keep the private mobile phone number confidential and not to share w ith anyone else, including Actelion. 
12.[ADDRESS_1046157] patient  status at any time point during the course of 
the study. 
While
 entering the data, the investigator/delegate will be instantly alerted to data queries 
by [CONTACT_42940]. Additional data review will be  performed by [CONTACT_763433]. If discrepant data are detected, a query specifying the problem and requesting 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 82/[ADDRESS_1046158] 2017- 000216- 42 
Doc No D -18.398  
 
clarification  will be issued and visible to the investigat or/delegate via the  eCRF . All 
electronic queries visible in the system either require a data correction (when applicable) 
and/or a response from the investigator/delegate to clarify the queried data directly in the  
eCRF , or simply a data correction in the  eCRF . The investigator/delegate must, on 
request, supply Actelion with any required background data from the study documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the case of health authority queries, it is also necessary to have access to the complete study records, provided that patient  confidentiality is 
protected.  
This process will continue until database closure. 
Laboratory samples will be processed through a central laboratory and t he results will be 
electronically sent to Actelion.  
Data co
llected by [CONTACT_763434]. The data will be transferred to Actelion at the end of the study. The 
vendors will not use the data for any purpose not related to the conduct of the clinical study AC
-065A404.  
AEs
 are coded according to the latest MedDRA  used by [CONTACT_180494]. 
After the database has been declared complete and accurate, the database will be closed. Any changes to the database after that time may only be made as described in the appropriate Actelion QS docs. After database closure, the investigator will receive the eCRF s of the patient s of his/her site (including all data changes made) on electronic 
media or as a paper copy.  
[ADDRESS_1046159] versions, respectively, ICH
-GCP
 Guidelines, the principles of the 
“Declaration of Helsinki ” (currently 2013 version), and with the laws and regulations of 
the country in which the study is conducted. 
13.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document(s) provided to the patient  (such as the I CF) to an IEC/IRB. Approval from the committee/board must be 
obtained before starting the study, and must be documented in a dated letter to the 
investigator, clearly identifying the study, the documents reviewed , and the date of 
approval. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 83/[ADDRESS_1046160] also be 
submitted as amendments by [CONTACT_42942]/IRB in accordance with local 
procedures and regulations [see Section 13.6].  
A list of members participating in the IEC/IRB meetings must be provided, including the names, qualifications, and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation.  
If a member of the study personnel was present during an IEC/IRB meeting, it must be 
clear that this person did not vote. 
13.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to the latest versions of the ICH
-GCP a
nd Declaration of Helsinki guidelines and local 
regulations from each individual participating in this study and/or legally designated representative. The investigator/delegate must explain to patient s that they are completely 
free to refuse to enter the study, or to voluntarily withdraw from the study at any time for any reason without having to provide any justification. Special attention shall be paid to 
the information needs of specific patient  populations and of individual patient s, as well as 
to the methods used to give the information. Adequate time shall be given for the patient  
and/or legally designated representative to consider his or her decision to participate in the study and it shall be verified that the patient  has understood the information (e.g., by 
[CONTACT_763435]). 
The I
CF will be provided in the country local language(s). 
Site personnel authorized to participate in  the consent process and/or to obtain consent 
from the patient  and/or legally designated representative will be listed on the Delegation 
of Authority form  supplied by [CONTACT_180494]. A study physician must always be involved in 
the consent process. 
The p
atient  and/or legally designated representative and authorized site personnel listed 
on the Delegation of Authority form supplied by [CONTACT_208288], personall y date, and 
time (if the first study -mandat
ed procedure is to be performed on the same day informed 
consent is obtained) the ICF before any study -related
 procedures (i.e., any procedures 
required by [CONTACT_760]) begin.  
A copy
 of the signed and dated ICF is given to the patient  and/or legally designated 
representative; the original is filed in the site documentation. The informed consent process must be fully documented in the patient ’s medical records. This must include at a 
minimum the study reference, the patient  number, the date and, if applicable, time when 
the patient  was first introduced to the study, the date and, if applicable, time of consent, 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 84/[ADDRESS_1046161] 2017- 000216- 42 
Doc No D -18.398  
 
who participated in the consent discussion, who consented the patient , and any additional 
person present during the consent process (e.g., patient ’s family member[s]), and the 
information that a copy of the signed ICF was given to the patient  / legally designated 
representative.  
If the site intends to recruit patient s who are considered as vulnerable (e.g., patient  cannot 
read or write, does not speak or understand the ICF language), additional measures must 
be implemented in order to ensure patient ’s rights are respected and the consent obtained 
is legally valid. Actelion, the regulatory authorities (if applicable), and the IEC/IRB must be informed prior to the recruitment. The consent process (e.g., involvement of an impartial witness) must be fully described, submitted to, and approved by [CONTACT_6179]/IRB, according to procedures and before patients are recruited.  
13.4 Compensation to patient s and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against claims arising from the study, except for claims that arise from malpractice and/or negligence.  
The c
ompensation of the patient  in the event of study -rela
ted injuries will comply with 
applicable regulations. 
13.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the IEC/IRB and/or the regulatory author ity
-appr
oved version of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the patient . 
If 
a protocol deviation occurs, the investigator/delegate will inform Actelion or its 
representative in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. Deviations considered to be a violation of ICH
-GCP
 must be reported to the IEC/IRB and regulatory authorities according to 
Actelion or (overruling) local requirements. 
All
 protocol deviations will be reported in the Clinical Study Report (CSR). IECs/IRBs 
will be provided with listings of protocol deviations as per local requirements. 
13.[ADDRESS_1046162] be submitted to the IEC/IRB and regulatory authorities, according to their requirements. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 85/[ADDRESS_1046163] 2017- 000216- 42 
Doc No D -18.398  
 
13.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the 
reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accu rate, legible, contemporaneous, original (or certified 
copy), attributable, complete, consistent, enduring, and available when needed. 
These records are to be classified into two different categories of documents: ISF and 
patient s’ source documents.  
These records must be kept by [CONTACT_721097] ’s requirements (i.e., as specified in the clinical study agreement), and national 
and/or international regulations, whichever would be the longest period. If the investigator cannot guarantee this archiving requirement at the site for any or all of the 
documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store these documents outside the site, so that 
they can be retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion 
must be notified in advance. 
If the site is using an electronic/computerized system to store patient  medical records, it 
can be used for the purpose of the clinical study if it is validated (as per [ADDRESS_1046164]) and if the CRA has been provided personal and restricted access 
to study patient s only, to verify consistency between electronic source data and the  eCRF  
during monitoring visits.  
If th
e site is using an electronic/computerized system to store patient  medical recor ds but 
it could not be confirmed that the system is validated or if the CRA could not be provided access to the system, the site is requested to print the complete set of source data needed for verification by [CONTACT_2689]. The print
-outs m
ust be numbered, stapled together with a 
coversheet, signed and dated by [CONTACT_093]/delegate to confirm that these certified copi[INVESTIGATOR_215182]. The printouts will be considered as the official clinical study r ecords and must be filed either 
with the patient ’s medical records or with the patient ’s eCRF . 
In o
rder to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the 
CRA must be able to observe this process and confirm that the comparison of the source documents and the certified copy did not reveal inconsistencies. The CRA does not need to verify this process for all data of all patient s but at least for some of them (e.g., first 
patient ; regular check during the study of critical data like inclusion/exclusion criteria, 
endpoints for some patients) as per Actelion ’s instructions. If it were not possible for the 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 86/[ADDRESS_1046165] 2017- 000216- 42 
Doc No D -18.398  
 
CRA to observe this process, it would not be possible to rely on the site ’s certified copi[INVESTIGATOR_42875].  
13.8 Monitoring 
Prior to study start, a site initiation visit (SIV) will be performed after the required 
essential study documents are approved by [CONTACT_180494]. The study treatment will be shipped to the site upon approval of the required essential documents. 
The PI [INVESTIGATOR_223138]. Site  Information Tech nology support should also be 
available during the SIV.  
The S
IV must be completed before the site can start the screening of study patient s. 
Following the SIV, a copy of the completed initiation visit report and follow -up le
tter 
will be provided to the PI [INVESTIGATOR_42876]. 
Duri
ng the study, the CRA will contact [CONTACT_763436] s ite regularly and must be permitted, 
on request, to have access to study facilities and all source documents needed to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the  eCRF s and other protocol
-rel
ated documents. Actelion monitoring 
standards require full verification that informed consent has been provided, verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency of the source data with the  eCRF s will be performed according to the 
study
-spe
cific monitoring guidelines. The frequency of the monitoring visits will be 
based on patient  recruitment rate and critical data -colle
ction times.  
The P
I must ensure that the  eCRF  is completed after a patient ’s visit (site visit or 
telephone call), and that all requested patient  files (e.g., ICFs, medical notes/charts, other 
documentation verifying the activities conducte d for the study) are available for review 
by [CONTACT_2689]. The required site personnel must be available during monitoring visits and allow adequate time to meet with the CRA to discuss study
-relat
ed issues.  
The i
nvestigator agrees to cooperate with the CRA(s) to ensure that any issues detected in 
the course of these monitoring visits are resolved. If the patient  is hospi[INVESTIGATOR_42878] a 
hospi[INVESTIGATOR_42869], the investigator is responsible for contact[CONTACT_42948][INVESTIGATOR_215185], in accordance with local regulations.  
A clo
se-out v
isit will be performed for any initiated site when there are no more active 
patient s and all follow -up is
sues have been resolved. In case a site does not enroll any 
patient s, the close -out v
isit may b e performed prior to study database closure at the 
discretion of Actelion. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 87/[ADDRESS_1046166] be kept by [CONTACT_208289], ICH
-GCP
, as well as instructions from Actelion. If the site needs to transfer 
the ISF to another location and/or if site facility can no longer store the ISF, the PI [INVESTIGATOR_208164].  
If th
e PI [INVESTIGATOR_208165], or if the site will relocate, the CRA must be notified as soon as 
possible. 
13.10  Audit  
Actelion ’s/CRO ’s representatives may audit the investigator site (during the study or 
after its completion). The purpose of this visit will be to determine the investigator ’s 
adherence to ICH -GCP
, the protocol, and applicable regulations; adherence to Actelion’ s 
requirements (e.g., standard operating procedures ) will also be verified. Prior to initiating 
this audit, the investigator will be contact[CONTACT_180536] a time for the audit.  
The i
nvestigator and site personnel must cooperate with the auditor(s) and allow access to 
all study documentation (e.g., patient  records) and facilities.  
13.11  Inspections 
Health authorities and/or IEC/IRB may also conduct an inspection of this study (during 
the study or after its completion) at the site.  
Should an inspection be announced by a health authority and/or IEC/IRB, the investigator must immediately inform Actelion  (usually via the CRA) that such a request has been 
made.  
The investigator and site personnel must cooperate with inspector(s) and allow access to all study documentation (e.g., patient  records) and study facilities.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 88/[ADDRESS_1046167] the key elements of this protocol and the summary of results on 
Actelion ’s Clinical Trial Register and within the required timelines on publically 
accessible databases (e.g., clinicaltrials.gov, EU database), as required by [CONTACT_42951]. 
Stud
y results will be documented in a CSR that will be signed by [CONTACT_215270] (or PI [INVESTIGATOR_208166] -cente
r studies).  
In 
accordance with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -revi
ewed journal. Study results can be 
submitted for presentation at a congress before submission to a peer -revi
ewed journal. 
The
 Coordinating Investigator [INVESTIGATOR_763385] a nalysis of the 
data and discuss the interpretation of the study results with Actelion personnel prior to submission to a peer
-revi
ewed journal or presentation at a congress.  
Author
ship will be determined in accordance with the International Committee of Journal 
Editors criteria, and be based on: 
• substantial contributions to the conception or design of the study, or the acquisition, 
analysis, or interpretation of data; and 
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
The l ist of authors of any publication of study results may include representatives of 
Actelion and will be determined by [CONTACT_11402].  
Any s
tudy-rela
ted publication written independently by [CONTACT_215271] [ADDRESS_1046168] alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Nei ther the institution nor the investigator should permit publication 
during such a review period. 
Acte
lion’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents/corporate/policies -cha rters/policy -scie ntific -
publications.pdf. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 89/[ADDRESS_1046169] 2017- 000216- 42 
Doc No D -18.398  
 
14 REFERENCES 
[Benza 2010] Benza RL, Miller DP, Gomberg -Maitland M, Frantz RP , Foreman AJ, 
Coffey CS. Predicting survival in pulmonary arterial hypertension insights from the 
registry to evaluate early and long -term pulmonary arter
ial hypertension disease 
management (REVEAL). Circulation. 2010;122:164 -172.  
[Chadha 2009]  Chadha C, Pritzke
r M, Mariash CN. Effect of epoprostenol on the thyroid 
gland: enlargement and secretion of thyroid hormone. Endocr Pract. 2009;15:   
116-21. 
[FDA 2009] Food and Drug
 Administration. Guidance for Industry. Patient -reported 
outcome measu
res: use in medical product development to support  labeling claims.  
December 2009 . Available from: 
http://www.fda.gov/downl
oads/Drugs/Guidances/UCM193282.pdf. Accessed 
8 February 2017. 
[Freedson 1998] Freedso
n PS, Melanson E, Sirard J. Calibration of the Computer Science 
and Applications, Inc. accelerometer. Med Sci Sports Exerc. 1998;30:777 -81. 
[Galiè 2015a ] Galie N, H
umbert M, Vachiery JL , et al. 2015 ESC/ERS Guidelines for the 
diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respi[INVESTIGATOR_3764] (ERS)  Endorsed by: 
[CONTACT_763437] (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Resp J 2015;46:903
-975. 
[Galiè 2015b] Galiè N, 
Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughli n 
VV, et al . Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial 
Hypertension. N Engl J Med. 2015;373:834 -44. 
[Godfrey 2008]  Godfrey A , C
onway R , Meagher D , OLaighin G . Direct measurement of 
human movement by [CONTACT_91152]. Med Eng Phys.  2008;30:1364 -86. 
[Gomez -Arroyo 2015]  Gomez -Arroyo J, Sakaga mi M,
 Syed AA, Farkas L, Van Tassell 
B, Kraskauskas D, et al. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J. 2015;45(2):449
-62. 
[Hoeper 2013] Hoeper MM, B
ogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M . 
Definitions and Diagnosis of Pulmonary Hypertension. J Am Coll Cardiol. 2013;62:D42
-50. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 90/[ADDRESS_1046170] 2017- 000216- 42 
Doc No D -18.398  
 
[Humbert 2004] Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial 
hypertension. New Engl J Med. 2004;351:142 -136.  
[ICH
 M3]  ICH M3 (R2) Guideline: Guida nce on non -clin
ical safety studies for the 
conduct of human clinical trials and marketing authorization for pharmaceuticals. 
11 June 2009 
[Ky
lhammar 2014] Kylhammar D, Persson L, Hesselstrand R, Rådegran G. Prognosis 
and response to first -line s
ingle - and com
bination therapy in pulmonary arterial 
hypertension. Scand Cardiovasc J. 2014;10:1 -23. 
[Ma
rvisi 2013] Marvisi M, Balzarini L, Mancini C, Mouzakiti P. Thyroid gland and 
pulmonary hypertension. What’s the link? Panminerva Med. 2013; 55:93 -7. 
[Ma
inguy 2011] Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment 
of daily life physical activities in pulmonary arterial hypertension. PLoS One. 2011; 6(11):e27993. 
[McCollister  2016] McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, 
Schüler  R, et al. 
Deve
lopment of the Pulmonary Arterial Hypertension -Sym
ptoms 
and Impact (PAH -SYMP
ACT®) questionnaire: a new patient -repor ted outcome 
instrument for PAH. Respir Res. 2016;17:72. 
[McK
enna 2006] McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR): A measure of health -rela
ted quality 
of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15:103–115. 
[Okum
us 2016]  Okumus G, Aslan GK, Arseven O, Ongen G, Issever H, Kıya n E. The 
role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. Clin Respir J. 2016; Epub 2016 May 5. 
[Oudi
z 2013] Oudiz RJ. Death in pulmonary arterial hy pertension. Am J Respir Crit Care 
Med. 2013;188(3):269 -70. 
[Pug
h 2012] Pugh ME, Buchowski MS, Robbins IM, Newman JH , Hemnes AR . Physical 
activity limitation as measured by [CONTACT_763438]. 
CH
EST 2012;142:1391 -1398. 
[Pul
ido 2013] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, 
et al. Mac
itentan and morbidity and mortality in pulmonary arterial hypertension. N 
Engl J Med. 2013;369:809 -18. 
[Sel
exipag IB] Investigator’ s brochure for selexipag, version 13. Actelio n 
Pharmaceuticals Ltd, September 2018. 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 91/[ADDRESS_1046171] 2017- 000216- 42 
Doc No D -18.398  
 
[Sitbon 2015] Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al . 
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 
2015;373:2522 -33.  
[Ul
rich 2012]  Ulrich S, Fischler M, Speich  R, Bloch KE. Wr
ist actigraphy predicts 
outcome in patients with pulmonary hypertension. Respi[INVESTIGATOR_1516]. 2013;86:45 -51. 
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 92/[ADDRESS_1046172]  
Please note: Per study requirement, patients must be at trough levels for study treatment. 
Trough level of study treatment (selexipag) is defined as : the last dose has been taken not 
less than 8 hours prior to the 6MWT. 
Background 
This
 document is an adaptation from the American Thoracic Society (ATS) guideline on 
the 6MWT ( ATS statement: guidelines for the six -minute
 walk test. Am J Respir Crit  
Care Med. 2002;166:111 -17). 
 
Too
l description  
• A s
elf-paced t
est that measures the distan ce that a subject can quickly walk on a 
flat, hard surface in a period of 6 minutes (the 6MWD).  
• As
sesses the submaximal level of functional capacity.  
• Evaluates the global and integrated responses of all the systems involved during 
exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism.  
Contraindications and safety issues 
Absolute contraindications for the 6MWT include: 
• Unstable angina and/or myocardial infarction during the previous month. Stable 
exertional angina is not an absolute contraindication for a 6MWT, but subjects with these symptoms must perform the test after using their antiangina medication, and rescue nitrate medication must be readily available.  
Relative contraindications include: 
• Resting HR  of more than 120 beats/min after [ADDRESS_1046173]. 
• Uncontrolled hypertension: S BP of >180 mm Hg +/− DBP  > [ADDRESS_1046174] enabling to call for help if needed. Access to a crash cart, as well as medications to treat angina, bronchospasm, and severe 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 93/[ADDRESS_1046175] be available (e.g., aspi[INVESTIGATOR_248], subligual nitroglycerine, oxygen, 
albuterol metered dose inhaler or nebulize r). 
Care must be taken to evaluate safety in ambulation prior to the 6MWT, to ensure that the subject is safe to proceed.  
Reasons for immediately stoppi[INVESTIGATOR_007] a 6MWT include the following: ( 1) chest pain, 
(2) intolerable dyspnea, ( 3) leg cramps, ( 4) staggering , (5) diaphoresis, and ( 6) pale or 
ashen appearance. Any reason for discontinuing the test needs to be recorded. 
Puls
e oximetry is optional. If it is performed, measure and record baseline HR  and 
oxygen saturation and follow manufacturer ’s instructions to maximize the signal and to 
minimize motion artifact. The oxygen saturation must not be used for constant monitoring during the exercise (no intra
-test
 measurements). The technician must not 
walk with the patient to observe the oxygen saturation. 
Gene
ral Instructions  
The 6MWT needs to be performed indoors, along a long, flat, straight, enclosed corridor 
with a hard surface that is seldom traveled. The walking course must be free of obstacles. 
If a suitable indoor corridor cannot be found, the test may be performed outdoors if the 
weather is comfortable. A permanent, dedicated course is ideal. The use of treadmill and a continuous course is not allowed.  
The w
alking distance used for the test needs to be 30 meters (not shorter than 20 meters) 
in length. This d istance needs to be marked every [ADDRESS_1046176] be 
marked with a cone. A starting line, which marks the beginning and the end of each 60–m lap, needs to be marked on the floor using brightly colored tape. Ensure that the subject walks the same course on each re
-test. 
The
 staff member administering the 6MWT  needs to stand near the starting line during 
the test and must not walk with the subject, and not get distracted during the conduct of this test (e.g., talk to anyone). Intermittent r est periods are allowed if the subject can no 
longer continue. If the subject needs to rest, he/she may pause, lean against the wall and continue walking whenever he/she feels able. The [ADDRESS_1046177].  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 94/[ADDRESS_1046178] always be conducted under the same 
conditions throughout the clinical trial (e.g., same corridor). Whenever possible, repeat testing for an individual subject needs to be conducted by [CONTACT_180546], and preferably at about the same time of the day to minimize variability. A warm up period before the test must not be performed.  
Training tests  
For subjects who have never performed a 6MWT previously, a training test is 
recommended before the 6MWT, due to a learning effect when performing the test.  
Timing  
The interval between training tests must be at least [ADDRESS_1046179] 2 hours. More than two 6MWTs cannot be performed on the same day.  
Required equipment  
Emergency call tool  
Countdown timer (or stop watch)  
Mechanical lap counter  
Two small cones to mark the turnaround points  A chair that can be easily moved along the walking course  
Worksheets on a clipboard  Sphygmomanometer  Automated electronic defibrillator  Source of oxygen  Oximeter (optional)  
Subject preparation  
Medications type, dose and number of hours taken before the test must be recorded. Restrictions in medications need to be described. Certain medications need to be stable prior to the test (oxygen, diuretics, etc.).  
The subject needs to wear comfortable clothing and appropriate walking shoes.  
The meals preceding the test need to be light, and the subject must not have exercised 
vigorously within [ADDRESS_1046180] is used 
to taking bronchodilators before a walk, he/she must take them 5–[ADDRESS_1046181].  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 95/[ADDRESS_1046182] (i.e., same application route and/or delivery device and same way of carrying the delivery device) and the flow rate remains constant. However, from [ADDRESS_1046183] stand and rate their baseline dyspnea using the Borg scale and instructions. 
Measurements  
Measurement of the 6MWD – Instructions to the subject  The person administering the test uses the following exact dialogue with the subject:  “The object of this test is to walk as far as possible for [ADDRESS_1046184] without hesitation. Now I ’m going to show 
you. Please watch the way I turn without hesitation.”  
(The tester demonstrates the walking and pi[INVESTIGATOR_180470] a cone briskly).  “Are you ready to do that? I am going to use this counter  to keep track of the number of 
laps you complete. I will click it each time you turn around at this starting line. 
Remember the object is to walk AS FAR AS POSSIBLE for 6 minutes, but don’ t run or 
jog. I will tell you when [ADDRESS_1046185] elapsed. Keep walking when I talk.”  
After these instructions are given to the subject, the person administering the test then 
asks:  
“Do you have any questions about the test?”  
“Please explain what you are going to do. ”  
“Are you ready? ”  
“Start now, or whenever you are ready .”  
As soon as the subject starts to walk, the tester starts the timer and writes down start time.  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 96/[ADDRESS_1046186] the time elapsed by [CONTACT_3041]:  
“You have 4 minutes to go.”  
“You have 2 minutes to go.”  When the timer is 15 seconds from completion, the tester says:  “In a moment I ’m going to tell you to stop. When I do, just stop right where you are and I 
will come to you .”  
When the timer alarm rings the tester says:  
“Stop!” If the subject stops walking during the test and nee ds a rest, the tester says:  
“You can lean against the wall if you would like; then continue walking whenever you 
feel able. ” Do not stop the timer. 
The tester walks over to the subject, marks the spot where the subject stopped, records 
the total distance w alked in the worksheet and congratulates the subject on good effort. 
Ask subject: “What, if anything, kept you from walking farther?” 
Rec
ord the post -wal
k Borg dyspnea index using the Borg scale and instructions. 
If using a pulse oximeter, measure oxygen saturation  and pulse rate from the oximeter.   
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 97/[ADDRESS_1046187] this: “ Please grade your level of shortness of breath using this scale. ”  
As s
oon as possible following the walk test, remind the subject of the breathing grade that 
he/she chose before the exercise and ask him/her to rate his/her shortness of breath using 
the scale again. The tester uses the following dialog:  
“I would like to use the following scale to indicate the maximal shortness of breath you 
had during the walk test (indicate the Borg scale).  
If there was no shortness of breath at all you would point to 0;  
if the shortness of breath was not very great you would choose from 0.5 to 2;  if you were somewhat more short of breath you would select 3;  and if the breathing was getting very difficult,  you would choose [ADDRESS_1046188] it was; [ADDRESS_1046189] ever 
experienced in your life. ” 
Borg rating  Perceived exertion  
0 
0.5 
1 2 3 4 5 6 7 8 9 10 Nothing at all  
Very, very slight (just noticeable)  
Very slight  
Slight (light)  
Moderate  
Somewhat severe  
Severe (heavy)  
 Very severe  
  Very, very severe (maximal)  
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 98/[ADDRESS_1046190] signs of right 
heart failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by [CONTACT_180547].  
   
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 99/[ADDRESS_1046191]® Questionnaire  
Pulmonary Arterial Hypertension- Sym ptoms and Im pact (PAH -SYMPACT) 
Questionnaire  
 
The questionnaire and a patient manual will be available in the local language(s).  
 
DAY [ADDRESS_1046192] 7 DAYS .   
 
Please do not skip any questions. There are no right or wrong answers to any of the questions.  
 
 
DAYS 2 -6 (Subsequent days prior to last day in week ) 
 
INSTRUCTIONS  
 
Today you will answer questions about your Pulmonary Arterial Hypertension symptoms over the 
PAST [ADDRESS_1046193] describes your experience with your 
symptoms.    
 Please do not skip any questions. There are no right or wrong answers to any of the questions.  
  
DAY 7  (Last day of week)  
 
INSTRUCTIONS  
 
Today you will answer questions about your Pulmonary Arterial Hypertension symptoms over the 
PAST [ADDRESS_1046194] 7 DAYS .   
 Please do not skip any questions. There are no right or wrong answers to any of the questions.  
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 100/[ADDRESS_1046195] 24 hours …  
 
Did you use oxygen?  
0  No 
1  Yes If yes: How many hours? _______  
  Answer the questions that follow based on your experiences regardless of whether you were 
using oxygen or not.  
 
2. In the past 24 hours …  
 How would you rate your shortness of breath ? 

0  No shortness of breath at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046196] 24 hours …  
 How would you rate your fatigue ? 

0  No fatigue at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046197] 24 hours …  
 How would you rate your lack of energy ? 

0  No lack of energy at all  
1  Mild  
2  Moderate  
3  Severe  
4  Very Severe  
   
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 101/[ADDRESS_1046198] 24 hours …  
 
How would you rate the swelling in your ankles or legs ? 
0  No swelling in ankles or legs at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046199] 24 hours …  
 
How would you rate the swelling in your stomach area ? 
0  No swelling in stomach area at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046200] 24 hours …  
 
How would you rate your cough ? 
0  No cough at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046201] 24 hours …  
 
How would you rate your heart palpi[INVESTIGATOR_814] (heart fluttering)? 
0  No heart palpi[INVESTIGATOR_814] (heart fluttering) at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046202] 24 hours …  
 
How would you rate your rapid heartbeat? 
0  No rapid heartbeat at all  
1  Mild  
2  Moderate  
3  Severe  
4  Very Severe  
 
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 102/[ADDRESS_1046203] 24 hours …  
 
How would you rate your chest pain ? 
[ADDRESS_1046204] pain at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046205] 24 hours … 
 
How would you rate your chest tightness ? 
[ADDRESS_1046206] tightness at all  
1  Mild  
2  Moderate  
3  Severe  
[ADDRESS_1046207] 24 hours …  
 
How would you rate your lightheadedness ? 
0  No lightheadedness at all  
1  Mild  
2  Moderate  
3  Severe  
4  Very Severe  
 
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 103/[ADDRESS_1046208] 7 days …  
 
Were you able to walk slowly  on a flat surface ? 
0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
[ADDRESS_1046209] 7 days …  
 
Were you able to walk quickly  on a flat surface ? 
0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
[ADDRESS_1046210] 7 days …  
 
Were you able to walk uphill? 
0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
[ADDRESS_1046211] 7 days …  
 
Were you able to carry things , such as bags or b askets?  
0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
4  No, not able at all  
   
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 104/[ADDRESS_1046212] 7 days …  
 
Were you able to do light indoor household chores , such as preparing food, cleaning 
surfaces, or tidying up?  
0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
[ADDRESS_1046213] 7 days …  
 
Were you able to wash or dress yourself? 

0  Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
[ADDRESS_1046214] 7 days …  
 
How much did you need help from others ? 
0  Not at all  
1  A little bit 
2  Some  
3  Quite a bit  
[ADDRESS_1046215] 7 days …  
 
Were you able to think clearly? 
0 Yes, with no difficulty at all  
1  Yes, with a little difficulty  
2  Yes, with some difficulty  
3  Yes, with much difficulty  
4  No, not able at all  
 
  
[STUDY_ID_REMOVED]
Selexipag (ACT -293987)  
Pulmonary arterial hypertension  
Protocol AC -065A404  
Version 2 
5 December 2018 , page 105/[ADDRESS_1046216] 7 days …  
 
How sad did you feel?  
0  Not at all  
1  A little bit  
2  Somewhat  
3  Very  
[ADDRESS_1046217] 7 days …  
 
How worried  did you feel?  
0  Not at all  
1  A little bit  
2  Somewhat  
3  Very  
[ADDRESS_1046218] 7 days …  
 
How frustrated  did you feel?  
0  Not at all  
1  A little bit  
2  Somewhat  
3  Very  
4  Extremely  
 
[STUDY_ID_REMOVED]